Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways

Hao Wang†, Junjie Pan†, Livnat Barsky‡, Jule Caroline Jacob³, Yan Zheng¹, Chao Gao¹, Shun Wang¹, Wenwei Zhu¹, Haoting Sun¹, Lu Lu¹, Huiiang Jia¹, Yue Zhao⁴, Christiane Bruns⁶, Razi Vago²* and Qiongzhu Dong¹* and Lunxiu Qin¹*

Abstract
Metastasis is a major contributor to cancer-associated deaths. It involves complex interactions between primary tumorigenic sites and future metastatic sites. Accumulation studies have revealed that tumour metastasis is not a disorderly spontaneous incident but the climax of a series of sequential and dynamic events including the development of a pre-metastatic niche (PMN) suitable for a subpopulation of tumour cells to colonize and develop into metastases. A deep understanding of the formation, characteristics and function of the PMN is required for developing new therapeutic strategies to treat tumour patients. It is rapidly becoming evident that therapies targeting PMN may be successful in averting tumour metastasis at an early stage. This review highlights the key components and main characteristics of the PMN and describes potential therapeutic strategies, providing a promising foundation for future studies.

Keywords: Pre-metastatic niche, Extracellular vesicles, Bone marrow-derived cells, Vascular alteration, Immunosuppression, Therapeutic strategies, Metastasis

Introduction
Tumour metastasis accounts for a large proportion of cancer-associated mortalities. Despite the progress that has been made in this area, the complex-stepwise process of tumour cell dissemination to target organs is yet poorly understood [1]. However, it is widely accepted that a pre-metastatic niche (PMN) offers an opportunity for primary tumour cells to efficiently adapt and survive, even within hostile microenvironments. As a result, tumour cells can multiply and enable the formation of subsequent metastasis [2]. The original concept of the PMN dates back to 1889 when Stephen Paget proposed the “seed and soil” hypothesis, that is, the tumour dissemination is governed by the crosstalk between tumour cells (the “seeds”) and host organ (the “soil”) [3]. A PMN is created by the primary tumour and can acquire permissive and supportive properties allowing colonization at target organs. The purpose of this review is to provide a perspective on our understanding of the characteristics and mechanisms involved in PMN establishment and progression.

Underlying mechanisms in the induction and formation of the PMN
Numerous studies have established that various cellular components and signalling pathways are responsible for its formation in different tumour models. The initiation and formation of the PMN are regulated through...
different mechanisms, allowing disseminating tumour cells to colonize future metastatic sites.

**Extracellular vesicles**

Extracellular vesicles (EVs), a collective term covering a variety of cell-derived membranous structures, can encapsulate and transport various cellular materials [4–8], mediating the crosstalk between primary tumour microenvironment and the PMN during the early stages of tumour metastasis [9, 10]. Tumour-derived EVs can alter the microenvironment in future metastatic sites by directly targeting organ-specific resident cells (liver Kupffer cells [11–14], hepatic stellate cells (hStCs) [12, 15], bone marrow stromal cells [16], tissue-resident macrophages [17, 18], lung fibroblasts [14, 15, 19–23], lung epithelial cells [14, 24], brain astrocytes [19], neurons [19] and microglia [25]). In this way, EVs facilitate PMN formation through induction of cytokines, chemokines and growth factors, extracellular matrix (ECM) remodelling and metabolic reprogramming. Apart from the pro-metastatic effects on these resident cells within specific pre-metastatic organs, EVs participate in the modulation of bone marrow-derived cells (BMDCs) and a variety of immune cells as well. EVs derived from highly metastatic melanoma cells are capable of reprogramming bone marrow progenitors toward a pro-vasculogenic and pro-metastatic phenotype through transferring MET oncoprotein [26]. Tumour-derived EVs can directly mediate cytotoxic immune cell dysfunction in the PMN, ultimately promoting tumour metastasis [27, 28]. The contribution of tumour-derived EVs to PMN formation may be exacerbated by anti-metastatic treatment like chemotherapy [29].

Vascular destabilization, caused by upregulation of vascular permeability and induction of angiogenesis, is one of many key steps during PMN establishment [2]. Therefore, the modulation of endothelial cell activity is a crucial aspect of the pro-metastatic effect of tumour-derived EVs. Recently, the importance of EVs in vascular destabilization has been highlighted. Tumour-derived EVs that contain proteins like epiregulin [30] and CEMIP [31] or RNA fragments such as miRNAs [32] and microRNAs (miR-105 [33], miR-25-3p [34], miR-181c [35]) directly or indirectly promote vascular permeability and angiogenesis in the PMN via the upregulation of proangiogenic factors and the modulation of tight junction proteins in endothelial cells. These aforementioned findings suggest that EVs from highly aggressive tumour cells lead to PMN formation through various mechanisms that depend on tumour type and future metastasis sites, whereas EVs released from non-metastatic tumour cells can potently inhibit metastasis. An example of such non-metastatic EVs is exosomes from non-metastatic melanoma cells, containing high levels of surface pigment epithelium-derived factor (PEDF). They stimulate an innate immune response, through the Nr4a1 transcription factor-driven expansion of Ly6C low patrolling monocytes in the bone marrow, resulting in a clearance of cancer cells in the PMN. More specifically, cancer cell clearance is brought about by the recruitment of NK cells and tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-dependent killing of melanoma cells by macrophages [36].

Alteration of the microenvironment of secondary organs by the secretion of EVs from non-tumour cells can be seen in various tissues. For example, carcinoma-associated fibroblast (CAF)-derived EVs possess a greater ECM remodelling ability than salivary adenoid cystic carcinoma (SACC)-derived EVs in inducing the formation of lung PMN and consequently increasing SACC lung metastasis [37]. Moreover, BMDC-derived EVs effectively potentiate the activation of hStCs to induce an immunosuppressive microenvironment in the liver for tumour metastasis [38]. EVs formed in metastatic organs may assist tumour cell proliferation and survival through the transmission of essential extrinsic signals to these cells [39]. Moreover, exosomal miR-23b delivered by bone marrow mesenchymal stem cells (MSCs) facilitates breast cancer cell dormancy within the PMN by suppressing target gene MARCKS [40]. Additional studies are needed to deepen our understanding of tighter links between EVs and the indispensable processes in PMN formation and even in consequently tumour cell extravasation and colonization at pre-metastatic sites.

**Cellular signalling pathways implicated in the PMN**

The establishment of the PMN at metastatic sites is facilitated by complex reciprocal signalling pathways among tumour cells from primary sites, myeloid cells from bone marrow, and resident cells from target metastatic sites at early stages of metastasis. The recruitment of various cells including BMDCs in target organs is a crucial event during PMN formation [2]. The chemokine receptors can transduce intracellular signals by binding with their homologous ligands, which is crucial for pre-metastatic recruitment of specific cells and the subsequent tumour colonization. The importance of CCR2/CCL2 signalling has been well identified in the pre-metastatic recruitment of BMDCs (Gr1+ inflammatory monocytes [41], CD11b+Ly6C low Ly6G+ monocytes [42], granulocytic myeloid-derived suppressor cells (MDSCs) [43] and monocyte MDSCs [44]). Moreover, CXCR2/CXCL1 signalling also participated in the recruitment of granulocytic MDSC in the PMN [45]. Additionally, CCR4/CCL17 or 22 and CXCR4/CXCL12 are vital chemokine signalling pathways for the recruitment of immune cells (regulatory T cells (Tregs) [46–48],...
neutrophils [49, 50] and dendritic cells (DCs) [48]) and participate in the metastatic colonization of tumour cells as well [16, 47, 48, 51–53]. In addition to chemokine signalling pathways, many other signalling pathways give rise to alterations in the cellular composition of future metastatic sites. STAT3 signalling in CD11b⁺ myeloid cells, for example, enable CD11b⁺ myeloid cells to mediate sustained survival and proliferation both of their own and of other stromal cells in the PMN [54, 55]. Moreover, receptor activator of NF-κB (RANK)/RANK ligand (RANKL) signalling [46] and prostaglandin E₂ (PGE₂)/EP3 signalling [48] in DCs lead to the expansion of Tregs and the recruitment of DCs, contributing to the formation of the PMN. Complement C5a/C5aR signalling induces the recruitment of MDSCs [56] and the proliferation but not the recruitment of alveolar macrophages [57] in the PMN, leading to an immunosuppressive environment favourable for tumour metastasis. In addition, fibronectin/VLA-4 signalling [51], peristatin/integrin α₅β₃ signalling [58] and p38 signalling [59] have proven to be responsible for the pre-metastatic accumulation of BMDCs.

Numerous studies have documented that signalling pathways in endothelial cells such as STAT3 signalling [60], Notch1 signalling [61], calcineurin-NFAT signalling [62] and CCR2/CCL2 signalling [42, 63] modulate the expression of cytokines, chemokines and adhesion molecules, which are, at least in part, responsible for adhesion and invasion of tumour cells in the PMN. Moreover, STAT3 signalling [64] and mTOR signalling [65] in lymphatic endothelial cells (LECs) within the PMN facilitate tumour cell extravasation and colonization. Apart from endothelial cells, signalling pathways in other organ-specific non-myeloid cells also have a role in the establishment of the PMN. In pre-metastatic bone, RANK/RANKL signalling creates an osteolytic PMN through the facilitation of pre-osteoclast maturation, which induces the release of soluble and insoluble factors from the skeleton, supporting cancer growth and survival in bone [66, 67]. Shh signalling [67] and Notch signalling [68] in osteoblasts confer proliferative advantages to bone metastatic tumour cells through the production of interleukin (IL)-6. In the pre-metastatic liver, STAT3 signalling in hepatocytes induces the expression of serum amyloid A (SAA) 1 and SAA2 that are crucial for PMN formation [69]. The fact that STAT3 signalling induces the secretion of factors responsible for the formation of PMN has also been demonstrated in tumour cells [54] and tumour-associated macrophages (TAMs) [70] within the primary tumour microenvironment. Tissue inhibitor of metalloproteinases (TIMP)-1/CD63 signalling in hStCs induces the expression of stromal-derived factor 1 (SDF-1, also known as CXCL12), which facilitates neutrophil recruitment for PMN formation [50]. Additionally, NF-κB signalling was reported to induce an inflammatory state in PMN to promote metastatic progression [15, 17, 23, 71]. A precise understanding of the contribution of signalling pathways to the dynamic process of PMN formation is a prerequisite to better understand the complex mechanisms involved and to design better therapeutic approaches targeting these signalling pathways to prevent tumour metastasis.

**Hypoxic control of the PMN**

Hypoxia and activation of hypoxia-inducible factor (HIF) signalling influence multiple steps within the tumour metastatic cascade [72]. Direct evidence for the role of hypoxia in the promotion of PMN formation is demonstrated by the lysyl oxidase (LOX) family proteins. During the early stage of tumour metastasis in breast cancer [73–75], colorectal cancer [76] and hepatocellular carcinoma [77], hypoxia acting as an important primary tumour microenvironmental factor regulates PMN formation through inducing the several members of LOX family, including LOX, LOX-like (LOXL) 2 and LOXL4. They can promote osteoclastogenesis in a RANKL-dependent or -independent manner and can modify ECM through catalysing collagen cross-linking in the PMN. By this, they are facilitating the recruitment of BMDCs and the following colonization of circulating tumour cells (CTCs). These findings demonstrate LOX family proteins as important biomarkers to identify pathways of PMN formation induced by hypoxia.

Importantly, the contribution of hypoxia to the formation of the PMN is not only through the LOX family proteins. Primary tumour hypoxia, for example, provides cytokines and growth factors capable of establishing a PMN through the recruitment of CD11b⁺Ly6CmedLy6G⁺ myeloid cells (driven partly by hypoxic tumour cell-derived monocyte chemotactic protein-1 (MCP-1), also known as CCL2) and a reduction in the cytotoxic effector functions of NK cell populations (attributed to the concomitant increase of CD11b⁺Ly6CmedLy6G⁺ myeloid cells) [43]. Moreover, HIF-1-induced carbonic anhydrase 9 (CA9) expression is a requisite for the mobilization of granulocytic MDSCs, driven by the granulocyte-colony stimulating factor (G-CSF), to the breast cancer lung PMN [78]. In addition to accurately regulating the secretion of cytokines and growth factors, hypoxia also is capable of augmenting EV secretion from breast cancer cells through HIF-dependent expression of small GTPase RAB22A [79], which may be associated with PMN formation. Moreover, the secretion of exosomes by prostate cancer cells under hypoxia can facilitate ECM remodelling and BMDC recruitment in target organs [80]. Further studies focused on the exact role of hypoxia and HIF-dependent signalling in PMN are
required to find several potential biomarkers and therapeutic targets that could be valuable for the detection and treatment of metastatic disease.

Components involved in the PMN

The illusive PMN is established by cooperative efforts of various players that eventually create an enabling microenvironment at which metastatic cells can anchor and survive under the proper spatial and temporal cues. The formation of this organ-specific niche takes place following ignition by the long-distance transmission of factors from the primary tumour, rearrangement of the ECM components at the distant site and assembly of cells to and within the recipient tissue. Upon development of the primary tumour and assembly of its microenvironment, a series of causative signals are released by the tumour cells to facilitate the complex steps towards the colonization of remote tissues [2, 59, 81].

Cellular components

The cellular assembly and involvement in the formation and development of the PMN are both complex and elusive. Furthermore, the spatiotemporal nature of these components is considered to vary between organs, tissues and may also be fine-tuned by specific niches [81, 82]. As a result, various pro-tumorigenic bone marrow-derived sentinel cells blaze the way for the development of the PMN.

Following the progression of the primary tumour and establishment of a flux of soluble factors such as transforming growth factor-β (TGF-β), VEGF-A, S100 and SDF-1, a variety of cells involve pre-metastatic recruitment. Kaplan et al. [51, 83] demonstrated that bone marrow-derived hematopoietic progenitor cells (HPCs) that express VEGF receptor (VEGFR) 1 are recruited at early stages of the metastatic development. Their arrival contributes to the establishment of focal permissive PMN in the lung before tumour invasion. These cells also co-express CD34, CD11b, c-kit, and Sca-1, which may support their stemness properties, along with their locomotion to defined PMNs within the target tissue. These cells also express integrin adhesion molecules, such as VLA-4 (α4β1), that support their localization in specific areas. Kaplan et al. [83] also suggested that accumulation and activation of the PMN is an evolving process that is further fuelled by these cells, for example by the production of matrix metalloproteinases (MMP) 9 that may degrade the basement membrane, accelerating the extravasation of more VEGFR1* cells into the niche. There is evidence that immature myeloid cells are also recruited to the PMN at early stages [84]. Some recent studies suggest that neutrophils are pivotal contributors for early development of the PMN. The role of neutrophils in the regulation of PMN formation has been thoroughly reviewed by Jablonska et al. [85].

Once the early settlers are embedded within the microenvironment, they further contribute to the local microenvironment remodelling and the activation of residential cells and BMDCs. Fibroblasts are indicated to be a major cellular component of the primary tumour microenvironment and also a pivotal member of the PMN. Under normal regulation, fibroblasts are classified as mesenchymal cells harnessed in the ECM. In cancer progression, they can be activated and have been termed as CAFs. Upon activation, local fibroblasts are triggered to produce various signalling molecules such as SDF-1, TGF-β, S100A4, IL-6, CCL2, fibronectin and MMPs, which acting as ECM modifiers can attract CXCR expressing cells and forge proangiogenic and antiapoptotic permissive microenvironment within PMN [51, 86–88]. It is important to note, however, that CAFs are composed of multiple subpopulations that come from various origins, including reprogrammed resident tissue fibroblasts, bone marrow-derived MSCs, pericytes, adipocytes, and endothelial cells. So that the expression of various commonly used fibroblast markers is extremely heterogeneous and varies strongly between different CAF subpopulations [89, 90].

Pericytes

Pericytes are a group of cells that can be identified within the areas of vasculatures, embedded in the basement membrane and closely associated with the vessel lining cells. In contrast to what was commonly thought, they do not serve solely as structural milieu, but, via adhesion belt and gap junctions directly interact with endothelial cells and also provide the source for paracrine signalling pathways [91, 92]. Under normal homeostasis, pericyte encrustation is crucial for vessel remodelling, maturation, and stabilization. They also participate in the regulation of blood flow and vessel permeability. It is therefore understood that under normal conditions there is a tight regulation to maintain the balance between proangiogenic and antiangiogenic quies. [93]. In addition to their role during normal development, they contribute directly or indirectly to tumour growth, metastatic spread, and resistance to therapy [94, 95]. Various tumorigenic effectors such as oxygen tension, acidic pressure, expression of VEGF (of which, mostly VEGF-A)/VEGFR, platelet-derived growth factor receptor (PDGFR) and others propel the pericytes towards the proangiogenic condition. Under these conditions, the pericytes increase their coverage to sustain the microenvironment remodelling, maturation, and stabilization. They also participate in the regulation of blood flow and vessel permeability.

Wang et al. Molecular Biomedicine (2021) 2:3
Page 4 of 32
antiangiogenic agents. However, some experimental evidence reveals the failure in the clinical trials attempting to block pericytes [96]. Taking into account the paradigm of pericytes biology, their role in the metastatic progression is not yet fully understood.

The entity of pericytes has evolved from being a mesodermal and ectodermal origin cell type, which seems only to function in mechanical support, to acting as endothelial cells that maintain vasculature stabilization and to being an active player that closely interacts to maintain endothelial cells. They release signals to the surrounding and play a pivotal role in the fabrication designated to perivascular niches. Strong evidence identifies pericytes as stem cells capable of forming several other cell types with angiogenic, myogenic, chondrogenic and osteogenic potential [97]. The discovery of multipotent capacities of perivascular populations led to the concept of the existence of a vessel-mural niche [98]. However, due to the absence of a unique marker, tracking pericycle lineage has traditionally proven to be difficult [98, 99]. Yamazaki et al. [100] demonstrated that a subpopulation within the embryonic skin tissue unexpectedly derives from endothelial- and hematopoietic-derived cell lines. These experiments suggest that during development the origin of tissue pericytes is heterogeneous. It is therefore suggested that even pericytes that originate from the same tissue, may be heterogeneous in their origin [100]. Herein we submit that the role of pericytes during the development of the PMN may also be heterogeneous and tissue-dependent. Additionally, more experimental work should be carried out in order to understand their involvement in the metastatic progression.

**Hematopoietic stem cells (HSCs)**

The differentiation of hematopoietic stem cells (HSCs) into mature cells is tightly controlled by the microenvironment of bone marrow, in which different stromal cells and ECM components are working in concert to regulate HSCs activity, including their mobilization, differentiation and quiescence. There are two distinct niches in the bone: the endosteal niche lining the bone surface and the perivascular niche around sinusoids. With regard to the perivascular niche, a variety of processes are working together to regulate HSCs. Some cell-regulating pathways, such as, Akt and p42/44 MAPK, can promote HSC expansion and self-renewal by upregulating IGFBP2, fibroblast growth factor (FGF) 2, BMP4 and DHH, and downregulating dickkopf (DKK1), which is an inhibitory factor of Wnt axis that controls HSCs self-renewal [99, 101, 102]. A variety of cell-cell and cell-ECM adhesion molecules such as E-selectin, E-cadherin and CD44 also take part in the regulation of HSCs within the perivascular niche. In cases of bone dwelling metastases, invading cells can take over both niches because like normal HSCs they can engage with the chemical, topological and molecular signalling of these niches [95]. It is now generally accepted that tumour cells are affected by oxygen tension, calcium flux and homing signalling such as SDF-1/CXCR4 and adhesion molecules, all of which mediate shuttling of cancer cells between the niches and between dormant and active states. However, the intricate influence of different bone marrow microenvironments on tumour development is currently under investigations.

**MSCs**

MSCs are the non-haematopoietic and multipotent cells with the capacity to differentiate into mesodermal lineages such as osteocytes, adipocytes and chondrocytes as well as ectodermal (neurocytes) and endodermal lineages (hepatocytes) [103]. Human MSCs were reported in bone marrow for the first time [104] and are continuously attracting attention because of their biotechnological and clinical potential [105]. Over a decade ago, MSCs was observed to be derived from a variety of tissues such as fat, skin, heart, muscle and liver. Interestingly, cells with MSC markers also express pericyte markers, so it was then suggested that all MSCs are pericytes [106] or derived from pericytes [107]. However, the progenitor hierarchy between MSCs and pericytes was recently challenged by different lineage tracing strategies. Guimarães-Camboa and colleagues showed that pericytes and vascular smooth muscle cells, although multipotent in vitro, do not behave as MSCs in vivo [94]. These findings contrast with previous studies that also used lineage tracing assays and give rise to an ongoing debate regarding the progenitor hierarchy between MSCs and pericytes [94, 108]. Both MSCs and pericytes take an active role in the formation of the PMN. To some extent, it may be suggested that this MSCs/pericytes tangle is a causative factor that regulates extravasation, adhesion and dormancy-reactivation.

It is well documented that MSCs closely interact with the tumour microenvironment and affect tumour progression. However, it should be considered that experimental publications may reflect contradicting results on the role of MSCs as tumour promoters or inhibitors and the molecular and cellular mechanisms of their interactions are poorly understood [109]. Several studies indicate that MSCs are significant players in the formation of distant metastatic sites. For example, Karnoub and colleagues [110] showed that CCL5 secreted by MSCs promotes lung metastasis of breast cancer through binding its receptor CCR5. It was also found that tumour-derived osteopontin induces the production of CCL5 by the MSCs [111]. As a part of the homing cascade, SDF-1 from MSCs and their terminal differentiation, osteoblasts, interacts with its
receptor CXCR4, which is highly expressed by bone metastasizing lineages like breast and prostate, facilitating tumour cells to colonize and survive in the bone microenvironment [105, 112, 113].

It is now widely accepted that just a small subset of invading tumour cells can survive the mechanical, physical and immunological pressures and harness the new terrain. This subpopulation of cells is characterized by de-differentiation and stem-like traits relating to the properties of metastasis initiation [114]. The metastatic capabilities of these cancer stem cells (CSCs) are remarkable since they are able to evade and survive the immune response, resist therapeutic agents, enter dormancy and reactivation. All of these stem-like properties create a well-adjusted “spearhead” that can penetrate, integrate and, later, further modulate the permissive PMN [115, 116]. The interaction between tumour cells and their niches including MSCs is critical for supporting CSC preservation and later development [117, 118].

**ECM components**

The ECM is a complex bio-lattice whose composition and structural characteristics vary among different tissues to support their specific functional needs. In many cases, the ECM is a highly organized 3D woven structure with a pivotal role in shaping the structural, biochemical and molecular landscape of many tissues. The ECM with its morphological architecture provides the physical properties for cell anchorage to direct and support cell motility during embryonic development, stem cell migration and repair of diseased tissue. In addition to connective tissues, the ECM is highly expressed in the basement membrane of endothelial cells and vasculature. The ECM consists of numerous molecules that, for a long time, have been considered to be mainly mechanical constituents and scaffolding for cellular anchorage and architectural integrity. However, in the last two decades it became apparent that rather than serving simply as a mechanical intercellular entity, the ECM is an active milieu affecting a wide array of intercellular and intracellular processes. These are being executed mainly by fibronectin and collagens [119, 120]. ECM constituents take part in cell-cell communication, adhesion, and various signalling cascades controlling the fate of stem cells during embryogenesis and normal tissue homeostasis [121, 122]. The role of the ECM in the context of development and maintenance of the stem cell niche is of great importance and the action of the niche with its wealth of causative stem cell signalling mechanisms should be tightly regulated in a spatiotemporal manner [123]. A large body of evidence shows that the alteration of the stem cell niche plays a key role in a number of diseases associated with tissue degeneration, ageing, and neoplasia [124]. In diseased tissues, particularly tumours, the ECM undergoes intensive modifications along with interplay with the primary tumour that heavily influence tumour progression.

Yet, it is not always clear which occurs first, abnormal ECM formation that nurses tumour development or abnormal cellular and molecular processes that ultimately alter ECM structure and function in such a way that enables the occurrence of a tumour supportive crosstalk. Beyond these short-distance interactions, tumour-derived factors have been recently shown to depart the tumour microenvironment, circulate through the body and exert effects on ECM within distant organs [125]. These, along with other long-distance modifications, act in concert to establish the PMNs. In this permissive microenvironment, ECM molecules can interact with the invading cells in different manners, such as mechanical 3D scaffolding, anchorage via cell surface receptors and release of entrapped growth factors and chemokines, which, in return, further prepares the PMN for cancer cells arrival [126–129]. Studies confirm that similarly to the primary tumour niche, the ECM and its components are essential players in tumour interactions and progression within the PMN. It is suggested that once they surpass a certain threshold, deregulated ECM dynamics may cause irreversible changes to the main ECM constitutes of a normal niche and convert it into a cancer-permissive microenvironment.

**Collagens**

Collagens, such as I, III, IV, V are primary ECM proteins. Their primary function is providing structural support and binding other ECM proteins. Collagens represent as much as 30% of the total mammalian protein mass [130]. Fibrillar collagens form fibrous structures mostly found in tendons, cartilage, skin and cornea. Each collagen fibre is made up of several subtypes of collagen as dictated by the particular tissue and function. Type I is the most abundant fibrillar collagen, found in connective tissues, such as skin, tendon, cornea and bone [130]. Type IV collagen is a key component of the basement membrane, which is found at the basal surface of epithelial and endothelial cells and is essential for tissue integrity [130]. Collagen I is heavily involved in processes such as wound repair and organ development [131]. As such, collagens take part in desmoplasia at metastatic sites where they may contribute towards the successful establishment of metastases. It is demonstrated that the architecture of the collagen scaffolds in tumours is severely altered. They are often linearized and crosslinked, reflecting elevated deposition and significant posttranslational modification [130, 132]. These collagen modifications further affect cellular metabolism, proliferation, differentiation, and apoptosis via signalling pathways, such as TGF-β/Smad. The crosstalk between
collagen and cancer cells is executed mainly by direct anchorage to the cancer cell receptors. Adhesion of collagen I and collagen IV to cancer cells impacts cancer progression. The cadherin family represents one typical cell adhesion molecule that is closely related to collagen activity. Collagen I stimulates E-cadherin upregulation to facilitate the migration of pancreatic ductal adenocarcinoma (PDAC) cells [126, 133]. It is therefore suggested that these modified assemblies are involved in priming the construction of the PMN.

**Fibronectin**

It is well documented that fibronectin genes are upregulated in tumour cells during the epithelial-mesenchymal transition (EMT). Fibronectin is also considered, in some cases, as a biomarker for more aggressive mesenchymal characteristics. However, the role of fibronectin in tumorigenesis and malignant progression has been highly controversial and conflicting data is spanning from a tumour-suppressive to a pro-metastatic role associated with poor prognosis. Interestingly, fibronectin matrix deposited in the tumour microenvironment promotes tumour progression but, paradoxically, is also related to a better prognosis. Tsung-Cheng et al. [134] also suggested that the expression of fibronectin indicates acquisition of stemness state and drug resistance under which tumour cells grow significantly slower. They proposed that fibronectin is involved in the suppression of early tumour growth and progression but promotes late cancer metastasis, which may explain some of the contradictory studies. Libring et al. [135] recently demonstrated a dynamic relationship between the tumour and stromal cells within the tumour microenvironment in which the levels and fibrillization of fibronectin in the ECM are modulated during the particular stages of metastatic progression. Fibronectin has been shown to play a central role in processes associated with tumour progression. In particular, integrin α5β1 and fibronectin have not only been shown to be upregulated in tumours but have also been reported to participate in tumour cell proliferation [136]. Fogelgren et al. [137] suggested that the fibronectin matrix may provide a specific microenvironment to regulate LOX catalytic activity and Erler et al. [74] demonstrated that in the case of lung metastasis, after secreted by primary breast tumours, LOX colocalized with fibronectin within the domain of the PMN where it catalyses crosslink collagen IV in the lung basement membrane.

**Hyaluronan (HA)**

Hyaluronan (HA), is a large, high-molecular-weight, linear GAG composed of 2000 to 25,000 disaccharide units of glucuronic acid and N-acetylglucosamine [138]. It is now well documented that HA is not just a space filler but a biomolecule having multifunctional capacities. HA is highly expressed during early development and regulates essential biological processes by mediating cell activities such as migration, proliferation and differentiation. In addition to its ability to expand its volume by many folds, other interactions and functions are being executed via an array of cell surface receptors, including the receptor for hyaluronan-mediated motility (RHAMM), Toll-like receptor (TLR) 4 and CD44, the prominent HA receptor [139]. CD44 isoforms are overexpressed in several cell types including CSCs, hence considered to have a role in cancer progression [140, 141]. Accumulating evidence indicates that CD44 isoforms, especially CD44v isoforms, are CSC markers and critical players in regulating the properties of CSCs, including self-renewal, tumour initiation, metastasis and chemoresistance. In addition, it is becoming evident that CD44 is a signalling hub that integrates physical stimuli with growth factor and cytokine signals and transduces signals to membrane-associated cytoskeletal proteins or to the nucleus. This allows regulation of a variety of gene expression signals affecting cell-matrix adhesion, cell migration, proliferation, differentiation, and survival [141]. Since CD44 binds to several ligands such as HA, osteopontin, chondroitin, collagen and fibronectin that can be modulated during metastatic progression, it represents an important affector of the PMN. In addition, during assembly of the PMN, CD44 is required for the CD44v6-mediated assembly of a soluble matrix that supports exosomes for activating target cells in the PMN [142]. McFarlane et al. [143] reported that CD44 increases the efficiency of distant metastasis of breast cancer. They demonstrated that the loss of CD44 attenuated tumour cell adhesion to endothelial cells and reduced cell invasion, but did not affect proliferation in vitro. Avigdor et al. [144] demonstrated crosstalk between CD44 and CXCXR4 signalling. They found that HA is expressed in human bone marrow sinusoidal endothelium and endosteme, the regions where SDF-1 is also abundant. This suggests a key role of CD44 and HA in SDF-1-dependent transendothelial migration of HSCs/HPCs and their final anchorage within specific niches of the bone marrow. It is therefore suggested that HA-CD44 and their effectors, which are taking an important role in the fine-tuning of various niches, are pivotal players in the formation and regulation of the PMN. However, further investigations should be carried out in order to shed light upon these important, yet elusive issues.

**Characteristics of the PMN**

PMN formation involves a series of dynamic changes in specific organs induced by tumour-derived factors and EVs during the early stages of tumour metastasis [9, 10, 145–148]. The secretion of various soluble factors and EVs, by primary tumours, allows mediation of the informational transfer from local to near or distant sites and
seems to be the earliest event in the formation of the PMN. It is then followed by the modification of local microenvironment, including the functional altering of resident cells, the remodelling of ECM and the recruiting BMDCs and other types of immune cells [2, 127, 149–151]. During this dynamic process, special characteristics of the PMN have been recognized as critical to favour efficient tumour cell colonization and outgrowth of nascent metastases (Fig. 1).

**Vascular alteration**

Accumulated studies have demonstrated that the vasculature at PMNs is remodelled to suitable for the extravasation of tumour cells. VEGF, Ang2 and MMPs are responsible for the disruption of vessel stability in the PMN. For example, pre-metastatic factors such as Ang2, MMP3 and MMP10, which are upregulated in the pre-metastatic lungs by primary tumours, can disrupt the vascular integrity synergistically to facilitate the extravasation of tumour cells [152]. In another preclinical experiment, Ang2 upregulation in the pre-metastatic lungs was identified as a result of calcineurin-NFAT signalling activation in lung endothelium, and as a link between increased VEGF in the lung and increased angiogenesis in the metastatic niche promoting lung metastases [62]. MMP9 provided by recruited Gr1^+^CD11b^+^ myeloid cells promotes decreased pericyte coverage and disruption of VE-cadherin junctions in vascular endothelium, contributing to aberrant and leaky vasculature in the pre-metastatic lung [153]. Additionally, miR-30s that modulate pre-metastatic lung vessels mainly through MMPs are downregulated in fibroblasts of pre-metastatic lungs, leading to vascular destabilization and subsequent extravasation and colonization of tumour cells [154].

The dysregulation of tight junctions is another crucial factor for the deconstruction of the integrity of endothelial barriers in the PMN. Breast cancer cell-derived exosomes containing miR-105, for example, increase metastasis at PMNs by destroying the endothelial cell barrier through downregulating the tight junction zonula.

---

**Fig. 1** The main characteristics of the pre-metastatic niche (PMN) can be recognized as vascular alteration, immunosuppression, inflammation, metabolic reprogramming, heterogeneity and organotropism.
occludens 1 (ZO-1) protein [33]. Exosomal miR-25-3p derived from colorectal cancer cells regulates the expression of VEGFR2, ZO-1, occludin and Claudin5 in endothelial cells by targeting KLF2 and KLF4, consequently promoting vascular alteration in the PMN [34]. Inflammatory factors such as SAA3 and S100A8 were reported to trigger the formation of regions of hyperpermeability via TLR4 and its coreceptor MD-2 in the pre-metastatic lungs, increasing pulmonary susceptibility to metastatic homing [63]. Moreover, uptake of CEMIP⁺ tumour exosomes by brain endothelial and microglial cells induces endothelial cell branching and inflammation in the perivascular niche by upregulating the proinflammatory cytokines encoded by Ptgs2, Tnf and Ccl/Cxcl, known to promote brain vascular remodelling and metastasis [31]. In addition, a marked increase in lymphatic vessel density and a specific capsular and subcapsular distribution are observed in pre-metastatic sentinel lymph nodes of patients with early cervical cancer [155], which highlights the important role of lymphatic vascular remodelling in PMN. Exosomal IRF-2 induces the release of lymphangiogenic factors VEGF-C by macrophages, promoting sentinel lymph node metastasis of colorectal cancer [156]. The LECs within the lungs and lymph nodes are affected by tumour-secreted factors and start to express CCL5, which is neither expressed in normal LECs nor in cancer cells, and VEGF, which enhances lung vascular permeability and induces lymph node angiogenesis, promoting metastatic extravasation and colonization [64]. Furthermore, heparin-binding factor midkine, secreted by tumour cells, facilitates lymphangiogenesis through paracrine activation of the mTOR signalling pathway in LECs, thus promoting metastasis progression [65].

Immunosuppression
As a significant barrier to metastasis, the immune system has a critical role in metastatic colonization in PMNs. Before their thriving in a future metastatic site, tumour cells must overcome immunological elimination by establishing an immunosuppressive PMN to protect them from induced apoptosis. Immunosuppression in the pre-metastatic lungs involves recruitment of MDSCs to these sites and regulation of immunosuppressive factors production, such as TGF-β and IL-10, which favours the generation of Tregs and polarization of CD4⁺ T cells to a Th2 type that renders CD8⁺ T cells dysfunctional [56, 58]. This data is consistent with a previous experimental result that Gr1⁺CD11b⁺ immature myeloid cells in pre-metastatic lungs decrease IFN-γ and elevate Th2 cytokine production [153]. In another experiment, recruited granulocytic MDSCs proved to be the main source of IL-10, which inhibits the activity of T cells in pre-metastatic lungs [157]. Furthermore, the reduction of cytotoxic effector functions of NK cells may also be attributed to the increase in granulocytic MDSCs in the pre-metastatic lungs [43]. Additionally, epithelial Notch1 signalling triggers CXCR2-dependent Ly6G⁺ neutrophil accumulation within the PMN and generates an immunosuppressive environment featured with decreased infiltrating CD8⁺ T cells [158]. In the pre-metastatic lymph nodes, DC-derived SDF-1 may be responsible for attracting Tregs to these sites, which influences the fate of metastasized tumour cells [48]. Moreover, recruited Tregs in bone marrow may form an immunosuppressive niche facilitating the bone metastasis [46]. Tissue-resident macrophages such as alveolar macrophages may also have important immunomodulatory functions in the PMN. CD11b⁺F4/80⁺ alveolar macrophages preconditioned by breast tumours not only inhibit Th1 and favour generation of Th2 cells that had lower tumoricidal activity than Th1 cells but also reduce the number and maturation of lung DCs by regulating TGF-β in the lung environment [57]. Microglia, as the major innate immune cells in the brain, have an important role in modulating the local immune response during brain metastasis. Microglia are reprogrammed by breast cancer towards a pro-metastatic phenotype, which upregulates immunosuppressive cytokines in microglia that inhibit T cell proliferation [25]. In addition to promoting the pre-metastatic recruitment of immunosuppressive cells, primary tumour cells can directly mediate the dysfunction of anti-tumour effector cells such as T cells and NK cells via EVs, leading to the suppression of anticancer immune responses in pre-metastatic organs [27, 28]. Tumour cells can evade immune surveillance by the expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T cells to elicit the immunosuppressive response [159]. Given that metastatic tumours can release EVs, mostly in the form of exosomes, that carry PD-L1 on their surface [160] and that PD-1 is upregulated in pre-metastatic sentinel lymph nodes [155], it is very likely that the immune dysfunction in the PMN might be induced by exosomal PD-L1 released by primary tumour cells. Altogether, suppression of local antitumor immunity and the contribution of regulatory immune cells in PMN ultimately result in immunosuppressive PMN formation to facilitate metastatic seeding.

Inflammation
Inflammatory alterations in target metastatic sites may facilitate dynamic evolution of the PMN and the ensuing invasion of target organs by tumour cells. In recent years, a variety of S100 family proteins have been found to play the role of inflammatory mediators in chronic inflammatory diseases, as well as soluble factors involved in the interactions between tumour and stromal cells
during the PMN formation [161, 162]. Proinflammatory S100A8 and S100A9, whose expression is induced by factors secreted from primary tumours such as TNF-α, TGF-β and VEGF-A, serve as recruiters of CD11b⁺ myeloid cells into the pre-metastatic lungs, in turn promoting metastasis formation [59]. SAA3, an important proinflammatory downstream mediator of TLR4 family of proteins, has a role in the accumulation of CD11b⁺ myeloid cells and can induce its own secretion by a positive feedback mechanism that depends on TLR4, a functional receptor for SAA3 in endothelial cells, macrophages and Clara cells within the pre-metastatic lungs [71, 163]. It has been found that an antagonist of the TLR4/MD-2 complex can inhibit both the recruitment of MDSCs and the induction of S100A8 and SAA3 in pre-metastatic lungs [164]. Moreover, SAA3 can also induce expression of the inflammatory cytokine TNF-α in both alveolar type II cells and macrophages, and TNF-α, conversely, directly activates the SAA3 promoter in alveolar type II cells [163]. Another study has reported that tumour-released S100A7 could be involved in the PMN formation, increasing tissue fibrosis, which may favour the implantation of BMDCs and, in the end, the colonization of the target organ by CTCs [165]. In addition, S100A4, another S100 family member, seems to induce SAA expression and other transcriptional targets in an organ-specific manner. S100A4 significantly increases the expression of SAA1, SAA3, RANTES, G-CSF, S100A8 and S100A9 in the liver, while increasing the expression of SAA1 and S100A9 but downregulates G-CSF and has a negligible effect on SAA3, RANTES and S100A8 in the lung [166]. These findings suggest that the reciprocal interplay of S100 proteins, SAA proteins and TNF-α serves to produce a proinflammatory milieu in PMNs that recruits BMDCs and subsequently attracts tumour cells, promoting metastatic progression.

**Metabolic reprogramming**

Dysregulated metabolism, one of the hallmarks of cancer, influences metastasis and has been shown to play a crucial role in PMN. It is well known that metastatic tumour cells require a specific pattern of energy, nutrient, and oxygen to compete with the resident niche cells, thus adapt to the microenvironments of local tissues to establish a metastatic colony. Tumour-derived EVs can modulate the metabolism of stromal cells within specific organs, contributing to the creation of a PMN that promotes the development of metastasis. Breast cancer-derived extracellular miR-122, for example, can suppress glucose metabolism of resident cells in the PMN through the downregulation of the glycolytic enzyme pyruvate kinase, thus facilitating metastasis [19]. Human melanoma-derived exosomes that contain miR-155 and miR-210 are capable of reprogramming the metabolism of stromal fibroblasts to increase aerobic glycolysis and decrease oxidative phosphorylation, consequently causing extracellular acidification of microenvironments in distal regions accessible to exosomes [167]. In addition to stromal cells within the PMN, bone marrow neutrophils seem to undergo dynamic metabolic changes. A recent study showed that bone marrow granulocytic MDSC-like neutrophils from the early stage of tumour-bearing mice had high glucose uptake, increased oxidative phosphorylation, increased tricarboxylic acid cycle flux and increased glycolysis, which resulted in a substantially greater production of ATP than that of neutrophils from tumour-free mice [168]. Obesity suppresses the expression of NK cell effector molecules by inducing metabolic reprogramming in NK cells to lipid metabolism [169], which may associate with immunosurveillance dysfunction in the PMN under the condition of obesity. Tumour cells need to adapt the activity of their metabolic pathways to the nutrients in the PMN as nutrient availability may differ between organs. In the liver, for example, colorectal cancer cells, by secreting creatine kinase, convert creatine and ATP into phosphocreatine that is subsequently taken up to generate intracellular ATP, which sustains the energetic requirements of colon cancer cells encountering hepatic hypoxia, allowing them to survive this barrier to metastatic progression [170]. Furthermore, colon cancer cells can upregulate aldolase B, an enzyme involved in fructose metabolism, to meet their need for energy during metastatic proliferation in the liver [171]. Thrombopoietin, as a component of the physiological environment derived mainly from the liver, can promote metastasis of colorectal tumour-initiating cells to the pre-metastatic liver through the upregulation of lysine catabolism in these tumour cells to generate glutamate for liver colonization [172].

**Heterogeneity**

It is becoming increasingly apparent that tumour cells are heterogeneous, which can cause differences in tumour growth, metastasis and drug sensitivity between patients, within the same patient and even within cells in the same tumour [173]. Similarly, PMNs are increasingly recognized as heterogeneous with specific subtypes of niche components governing the development or homeostasis of selective functions. Cellular constituents of the PMN may differ between experiments with the same type of primary tumour and the identical future metastatic organ. In some mouse models of breast cancer, pulmonary alveolar macrophages or TAMs contribute to the PMN in the lungs [57, 70]. However, in other studies, neutrophils are revealed to be the main immune cells recruited to the pre-metastatic lungs of mammary tumour-bearing mice, although these cells have a low frequency in the primary tumour microenvironment.
This diversity implies that the formation of the PMN is a dynamic process and the difference in results may be due to the timing of the experiments. A recent study has shown that immune cells arrive at the pre-metastatic lung in waves differentially and sequentially, and some of the immune cells are only transiently present in the tumours [176]. In addition, the immune system of the PMN may be profoundly distinct. Neutrophils are regarded as critical regulators within the PMN, but they have a paradoxical role in the niche. In some animal models, neutrophils in the pre-metastatic lung inhibit the development of both breast and renal cancer lung metastases [174, 177]. In contrast, neutrophils are also demonstrated to be the main component and driver of metastatic establishment within the pre-metastatic lung microenvironment in several mouse breast cancer models [175, 178]. The paradoxical effects neutrophils possess may be contributed to the dynamic changes they undergo during the formation of the PMN, which is supported by a recent finding that bone marrow neutrophils in the early stages of lung cancer are functionally different from those in the late stages [168]. Tumour-derived exosomes are functional disparate in the establishment of the PMN. Currently, a growing body of evidence suggests that most metastatic cancers produce exosomes that condition PMNs in distant microenvironments to cause immunosuppression within the PMN [9]. However, other studies have revealed that pre-metastatic cancer exosomes trigger immune surveillance, which causes cancer cell clearance at the PMN by patrolling monocytes [36, 179]. Furthermore, it was shown that breast cancer cells with metastasis to lung or bone preferentially use OXPHOS over glycolysis, whereas liver-metastatic breast cancer cells incorporate glycolysis as the predominant metabolic process [180]. Therefore, the PMN is a highly complex, integrated ensemble of numerous components with unique functions and responds differently to the specialized tumour microenvironment.

Organotropism

Different types of cancer present divergent tropisms to develop metastases in different organs. This organ tropism observed in metastasis, called “organotropism”, remains one of the most intriguing questions unanswered in cancer research. Recently, increasing numbers of studies attribute this organotropic metastasis pattern to the successful establishment of the PMN in specific organs, which educates and transforms the local milieu of the target organ into a microenvironment favourable for colonization and outgrowth of primary cancer cells. Organotropism in the establishment of the PMN may partly attribute to the different tendencies of ECM remodelling in various organs. For example, LOX has an important role of ECM remodelling in the pre-metastatic lungs while its expression and activity in other organs is reduced or remains unchanged, which is possibly explained by the high oxygen concentration in lung tissue that contributes to LOX enzymatic activity [181]. Moreover, fibronectin and periostin, the major ECM proteins, frequently deposit in the pre-metastatic lungs and increase metastasis by enhancing myeloid cell recruitment and through direct interactions with disseminated tumour cells (DTCs) [124]. Tumour-secreted growth factors and EVs may also dictate organotropic formation of the PMN. During primary Lewis lung carcinoma and B16-F10 melanoma growth, increased VEGF levels specifically in the lung, and no other organ microenvironments, trigger a threshold of calcineurin-NFAT signalling that transactivates Ang2 in lung endothelium, thus inducing angiogenesis in the pre-metastatic lungs [62]. Additionally, tumour-derived exosomes can prepare the PMN in an organ-specific manner due to distinct integrin expression patterns, through which it was concluded that exosomal integrins $\alpha_6\beta_4$ and $\alpha_5\beta_1$ are associated with lung metastasis, while $\alpha_6\beta_5$ with liver metastasis [14]. Furthermore, the site of BMDC recruitment is tumour type-specific. A previous study demonstrated that intradermal injection of Lewis lung carcinoma cells resulted in BMDC cluster formation limited to the lung and liver with no clusters in other organs, while the B16 melanoma tumour cells formed BMDC clusters in multiple tissues such as the lung, liver, testis, spleen and kidney, which are all common metastatic sites for this tumour [51]. In summary, primary tumour and stroma in future metastatic sites reciprocally influence each other and together determine the organotropism of the PMN.

Significance of the PMN in cancer metastasis

The existence of the PMN has a significant role in cancer metastasis. The matured PMN is well-prepared for the seeding and growth of DTCs at metastatic sites. The stepwise progression of metastatic colonization and macrometastasis formation requires further fine-tuned crosstalk between the microenvironment and the metastatic cancer cells. The PMN can not only facilitate metastatic cell progression directly but can also induce their dormancy at metastatic sites for later recurrence.

Dormancy and metastatic colonization

During metastatic colonization, cancer cells must shape themselves to better adapt to colonization and manipulate a favourable microenvironment at the metastatic site. Most of the DTCs undergo a state of dormancy when they arrive at a distant site, sustaining an equilibrium between growth and death. Dormancy is acquired through some pivotal traits of cancer cells and contributes to tumour recurrence years or even decades after...
primary tumour resection. DTCs prefer to remain in a dormant state instead of initiating outgrowth immediately, which helps DTCs resist cancer therapy, evading immune surveillance and survive for periods before entering a growth phase when colonizing [182, 183]. The fate of DTCs is a dynamic event that can be regulated by stromal cells, immune cells, ECM and a hypoxic microenvironment in PMN and can be controlled by intrinsic signalling such as endoplasmic reticulum stress, epigenetic and metabolism as well. A study demonstrated that breast tumour cell dormancy was regulated by perivascular niches in the lung, bone marrow and brain, in which endothelial-derived thrombospondin-1 induced sustained breast cancer cell quiescence. This suppressive cue was lost in sprouting neo-vascularization, which are characterized by reduced thrombospondin-1 expression and enhanced expression of pro-tumour factors periostin and TGF-β1 [184]. It has been found that differentiated osteoblasts can secrete soluble factors such as TGF-β2 and GDF10 that induce dormancy of prostate cancer cells via p38 MAPK activation in the bone metastatic niche [185]. DTCs of PDAC decreased the expression levels of major histocompatibility complex (MHC) class I, to help them evade immune surveillance [186]. In melanoma, CD8+ T cells have a key role in the maintenance of dormancy at the metastatic site, since deprivation of CD8+ T cells leads to a faster metastatic outgrowth [187]. Neutralization of IFN-γ, depletion of T cells or using PD-L1 blockade could reverse irradiation-induced dormancy in mouse models [188]. CXCL5 can promote the proliferation of breast cancer DTCs and its colonization in bone, in turn, blockade of CXCR2, the receptor of CXCL5, leads to DTCs dormancy [189]. During lung inflammation, two neutrophil extracellular trap (NET)-associated proteases, neutrophil elastase and MMP9, sequentially cleave laminin, which induces proliferation of dormant cancer cells by activating integrin α3β1 signalling [190]. Compared with primary colorectal tumours, collagen type I appears to be highly citrullinated in liver metastases, which leads to a decrease in migration and increase in adhesion of colorectal cancer cells and helps these cells to survive colonization [191].

In a perivascular niche, integrin-mediated interactions between DTCs with von Willebrand Factor (VWF) and vascular cell adhesion molecule-1 (VCAM-1) on the basal surface of bone marrow microvascular endothelium can protect DTCs from chemotherapy and promote bone metastasis [192]. Cell adhesion molecule L1 (L1CAM) activates Yes-associated protein (YAP) and myocardin-related transcription factor (MRTF) via engaging integrin β1 and integrin-linked kinase (ILK) in DTCs, which is a general requirement for the outgrowth of aggressive metastasis-initiating cells immediately after extravasation and of latent metastatic cells after exiting from quiescence [193, 194]. Versican produced by CD11b+Gr1+ myeloid progenitor cells in the pre-metastatic lungs stimulates mesenchymal-epithelial transition of metastatic tumour cells by attenuating phosphor-Smad2 levels, which results in elevated cell proliferation and accelerated metastases [195]. The research found that the activity ratio of ERK1/2 (extracellular signal regulated kinases) and p38 MAPK could switch on/off the dormancy of DTCs in human head and neck carcinoma. High expression of integrin αβ1, urokinase-plasminogen activator receptor (uPAR) and fibronectin induced activation of focal adhesion kinase (FAK) and Src kinase, thereby leading to high ERK/p38 ratio and the proliferation of dormant DTCs. In contrast, p38 MAPK activation may lead DTCs into a dormant state [196–199].

Recent studies prove that epigenetic alterations and non-coding RNAs (ncRNAs) regulate the cycles of dormancy and outgrowth of DTCs by mediating the activation of dormancy-associated master regulators. The orphan nuclear receptor (NR2F1) is a critical molecular regulator in dormancy maintenance of DTCs. NR2F1 could induce chromatin repression and quiescence of DCTs dependent on regulation of SOX9 and RARβ. Blockade of NR2F1 can interrupt DTCs dormancy and leads to tumour growth in metastatic sites [199]. In breast cancer cells, mitogen- and stress-activated kinase 1 (MSK1), a downstream effector of p38 MAPK, mediates the expression of key differentiation genes, including FOXA1 and GATA3 via easing the acetylation on Lysine 9 and 27 of histone 3, thereby facilitating DTCs proliferation and metastatic colonization [200]. The KDM family molecules, such as KDM2, KDM3B, KDM5B, KDM6 and KDM7, and histone deacetylases (HDACs) govern the dormancy or proliferation of DTCs through altered methylation and acetylation of histone 3 lysine residues, which affects the activation of key regulatory signalling and dormant DTCs reactivation [201–208]. In metastatic cells, PTEN-targeting microRNAs, derived from astrocytes in brain PMN, silenced its expression and increased the secretion of CCL2 chemokine, which led to IBA1-expressing myeloid cells recruitment and consequently led to the outgrowth of brain DTCs [39]. Metabolism alteration and hypoxic stress also have a critical role in regulating DTCs’ dormancy and metastatic colonization. Emerging evidence proves that activation of ferroptosis by glutathione peroxidase 4 (GPX4) may help cancer cells resist therapy and survive as “persister” cells. Co-treatment with kinase inhibitors and ferroptosis activators can eradicate drug-tolerant persister cancer cells [209, 210]. At distant metastatic sites, asparagine can increase the levels of HIF-1α and MYC when glutamine is scarce, which affects oxidant stress and EMT transition and induces
DTCs to proliferate. If other nutrients are deficient in PMN, asparagine can promote glutamine biosynthesis and shape DTCs to survive and colonize in metastatic sites [211, 212].

Remodelling the microenvironment for cancer metastasis

While DTCs arrive at the PMN from primary sites, they may encounter a hostile, anti-metastatic environment that induces apoptosis or necrosis. Thus, DTCs need to take an active role in inducing changes in the microenvironment to be able to survive and outgrow in the PMN. For initial survival, they directly or indirectly modulate the PMN by secreting factors that alter the composition of the niche and/or by instructing stromal cells in the niche to support the optimal metastasis-initiation. Tumours not only participate in the recruitment and expansion of immunosuppressive cell populations to create a permissive PMN but also modulate the function of immune cells towards a pro-metastatic phenotype to facilitate metastatic progression. Metastatic breast cancer cells, for example, can regulate the expression of inflammatory response genes in metastasis-associated macrophages (MAMs) in a VEGFR1-dependent manner, thus promoting metastatic growth [213]. Furthermore, a subset of VEGFR1+ MAMs that support angiogenesis and metastatic growth was identified in liver metastasis of colorectal cancer and found to be correlated with patient outcome [214]. MAMs expressing α4-integrins can promote breast cancer cell survival and metastatic growth via binding to the VCAM-1 on metastatic tumour cells [215]. Additionally, tissue-resident macrophages in omentum exhibit a functional diversification in the context of tumour growth and play a specific role in the malignant progression of DTCs and the development of invasive disease in a mouse model of metastatic ovarian cancer [216]. Similarly, neutrophils have been shown to be educated by metastatic microenvironment towards a metastatic-associated phenotype. In liver metastases of colorectal cancer, infiltrated metastasis-associated neutrophils expressing FGF2 promote the development of disorganized tumour vasculature and metastatic growth [217]. Moreover, it has also been found that neutrophils become more N2 polarized as breast cancer liver metastasis progresses and a greater fraction of neutrophils adopt an N2 phenotype when they are located close to the liver-metastatic lesions [218].

The crosstalk between metastatic tumour cells and stromal cells also plays an important role in the optimal modulation of metastatic progression. A study related to the cellular environment of metastatic breast cancer cells in the lung reported the presence of cancer-associated parenchymal cells, which exhibit stem cell-like features, express lung progenitor markers and exhibit multi-lineage differentiation potential and self-renewal activity [219]. In breast cancer, metastatic initiating cells mediate efficient lung fibroblast activation through thrombospondin-2 secretion, which is critical for efficient metastatic initiation within the lung tissue [220]. It has also been found that astrogliosis and neuroinflammation, physiologically instigated as a response of astrocytes to overcome brain tissue damage, is hijacked by brain-metastasizing tumour cells to support their growth [221]. In the liver metastatic niche, MAMs, by secreting granulin, activate hStCs into myofibroblasts that secrete periostin, consequently, turning the ECM into a fibrotic environment to support metastatic growth [222]. Moreover, breast cancer cells rely on the nutrient pyruvate to drive collagen-based remodelling of the ECM in the lung metastatic niche, supporting their own metastatic growth [223]. Lactate released by glycolytic breast carcinoma cells in the bone microenvironment is used as a fuel for the oxidative metabolism of osteoclasts, ultimately facilitating bone resorption without stimulating osteoclastogenesis to support metastatic growth [224]. Furthermore, the formation of blood and lymph vessels is conducive to environmental remodelling, which helps to provide an adequate supply for the initial tumour growth and subsequently metastasis. Accumulated studies demonstrated that the increased vascular permeability within the PMN is the initial step in the development of subsequent metastasis. In colorectal cancer, tumour-derived exosomal miR-25-3p in vascular endothelial cells promotes PMN formation, which dramatically induces vascular permeability as well as angiogenesis and enhances colorectal cancer metastasis in the liver and lung of mice [34]. In animal tumour models, the hyperpermeability of vessels within the PMN is associated with metastatic burden [152]. In pre-metastatic lungs, lung fibroblast-derived miR-30s stabilized pulmonary vessels and postponed metastasis. However, Skp2 directly targeted by miR-30s, could disrupt pulmonary vessels and promote lung metastasis [154]. Thus, the remodelling of the microenvironment by DTCs within a PMN in the secondary metastatic sites is competent to support the survival and outgrowth of DTCs, resulting in the pathological progression from micrometastases to significant macrometastases.

Metastasis tropism

Metastasis formation in vital organs is a fatal step of cancer progression and the leading cause of cancer-related mortality. Increasing clinical evidence reveals that certain tumour types preferentially form metastases to survive and outgrow in a number of organs. The commonly targeted organs of metastasis including bone, liver, brain, and lung have been reported to have their own specific PMNs [225] (Fig. 2).
Bone

Bone is the third most common site of metastasis for many types of solid tumours, among which breast and prostate cancer are the primary ones [226–228]. Beneficial interactions between tumour cells and various constituents of bone tissue can predispose bone tissues to subsequent tumour colonization and outgrowth [150]. The RANK/RANKL system is a major regulator in the formation of osteolytic bone metastasis [229]. In prostate cancer, RANK-mediated signalling establishes a PMN through a feed-forward loop, involving the induction of RANKL and c-Met, thus promotes cancer cells to colonize the bone [66]. MAOA provides prostate cancer cells with cell growth advantages in the bone microenvironment by stimulating IL-6 release from osteoblasts and triggers skeletal colonization by activating osteoclastogenesis through osteoblast production of RANKL [67]. In breast cancer, T cell-derived RANKL promotes tumour spread and assists bone metastases establishment [230]. Additionally, osteoclastogenesis can be driven by LOX independently of RANKL, leading to osteolytic lesions within the bone microenvironment that support the colonization of tumour cells and the formation of overt bone metastases [75]. Adhesion molecules and CXCR4/CXCL12 chemokine signalling also play an important role in the initiation of bone metastases. In prostate cancer, the CXCL12/CXCR4 axis is crucial for the initial establishment of bone metastases in the endosteal niche, which is severely compromised by the blockade of the CXCL12/CXCR4 axis [231]. Dormant breast cancer cells reside in specific bone marrow niches that regulate their entry into the bone marrow via E-selectin, while anchoring them to the microenvironment via CXCR4/CXCL12 axis [232]. Furthermore, this concept has also been validated in an osteogenic niche, where niche interactions, mediated by cancer-derived E-
cadherin and osteogenic N-cadherin, promote early-stage bone colonization of disseminated breast cancer cells [233]. In osteolytic bone metastasis of breast cancer, aberrant expression of VCAM-1, in part dependent on the activity of the NF-κB pathway, promotes the transition from indolent micrometastasis to overt metastasis [234]. Additionally, a balance between the expression of Axl and Tyro3 is associated with a molecular switch between a dormant and a proliferative phenotype of prostate cancer in bone metastases [235].

**Liver**

The liver is the main site of metastatic disease and its infestation is a major cause of death following gastrointestinal malignancies, such as colon, gastric, and pancreatic carcinomas as well as melanoma, breast cancer, and sarcomas [236]. The liver receives a dual blood supply from the hepatic portal vein and hepatic arteries and has a much lower sinusoid blood pressure gradient, which allows CTC access and facilitates their attachment to the sinusoidal endothelium for seeding [225]. Both recruitment of non-resident cells and coordination of liver resident cells are implicated in establishing a supportive liver microenvironment for upcoming tumour cell outgrowth. Epidermal growth factor receptor (EGFR), in exosomes secreted from gastric cancer cells, can be delivered into the pre-metastatic liver and is integrated on the plasma membrane of liver stromal cells including Kupffer cells and hStCs, which effectively triggers hepatic metastasis [237]. PDAC-derived exosomes that highly express macrophage migration inhibitory factor induce TGF-β secretion by Kupffer cells, which, in turn, promotes fibronectin production by hStCs. Fibronectin deposits subsequently promote the arrest of bone marrow-derived macrophages and neutrophils in the liver, initiating the formation of the PMN [11]. The activation of hStCs, as well as subsequent ECM remodelling, was also reported in the pre-metastatic liver of lung cancer [38]. The homing of integrin αvβ5-expressing exosomes to fibronectin-rich liver microenvironments stimulates Kupffer cells to produce proinflammatory S100A8 and S100P implicated in facilitating tumour metastasis [14]. Furthermore, other proinflammatory cytokines such as IL-6 were found to be released by Kupffer cells influenced by tumour-derived EVs and in association with liver metastasis of colorectal cancer [13]. VEGF-A secreted by colorectal carcinoma cells stimulates TAMs to produce CXCL1 that recruits CXCR2+ granulocytic MDSCs to form a PMN that promotes liver metastases. Importantly, liver infiltrating granulocytic MDSCs are able to promote tumour cell survival without the involvement of innate or adaptive immune responses [45]. High systemic TIMP-1 levels increase the liver susceptibility to metastasis by triggering the formation of a PMN through activation of hStCs and recruitment of neutrophils [49, 50]. It has been shown that hepatocytes coordinate myeloid cell accumulation and fibrosis within the liver and, in doing so, increase the susceptibility of the liver to metastatic seeding and outgrowth [69]. Moreover, the adherence of CTCs to fibronectin deposited on the luminal side of liver blood vessels influences the metastatic colonization process from the bloodstream and facilitates liver metastasis of colorectal cancer [237].

**Brain**

Brain metastasis most commonly arises from of lung cancer, breast cancer and melanoma [238]. The blood-brain barrier (BBB) regulates the homeostasis of the central nervous system by forming a tightly regulated neurovascular unit that includes endothelial cells, pericytes and astrocytic end-feet, which together maintain normal brain function [239]. Tumour cell interactions with the brain microenvironment determine organotropic metastasis through various mechanisms including governing cancer-specific signalling pathways involved in metastatic growth. Brain metastatic tumour cells can transfer the second messenger cGAMP to astrocytes via establishing carcinoma-astrocyte gap junctions, activating the STING pathway and production of inflammatory cytokines such as IFN-α and TNF, which activate the STAT1 and NF-κB signalling in brain metastatic cells, thereby supporting tumour growth and chemoresistance [240]. In addition to direct contact, a contact-independent communication mediated by exosomes between metastatic tumour cells and astrocytes was also reported to prime the successful outgrowth of breast cancer cells to form life-threatening metastases [39]. Brain metastatic cells are capable of triggering a phenotypic switch from normal astrocytes to tumour-associated astrocytes through the IL-1β-mediated NF-κB pathway, which, in turn, induces c-Met activation in tumour cells through the expression of hepatocellular growth factor (HGF), promoting survival and growth of brain metastatic cells [241]. Exosomal miR-503 derived from tumour cells promotes M1-M2 conversion of microglia through manipulating STAT3 and NF-κB signalling pathways, followed by enhancing their PD-L1 expression to suppress local immunity and thereby promote brain metastases of breast cancer [25]. The main property of a pre-metastatic brain also lies in BBB destruction that predisposes the brain as a metastatic target. Breast cancer cells can release EVs containing microRNAs such as miR-181c and miR-105 to disrupt BBB integrity by facilitating tight junction dysfunction, promoting the progression of brain metastasis [33, 35]. Furthermore, BBB disruption was also reported to be induced by exosomal CEMIP...
protein derived from lung and breast cancer [31]. Cathepsin S specifically mediates BBB transmigration of metastatic tumour cells through proteolytic processing of the junctional adhesion molecule, JAM-B [242]. A recent study reports that downregulation of SERPINB1, a protein elevated in brain metastases, led to a reduction in brain metastasis, suggesting that some niche-specific ECM proteins are also involved in metastatic tropism [243]. Additionally, a metastatic tropism analysis showed that intrinsic molecular features of metastatic precursors amongst CTCs can dictate organotropism of metastasis and identified semaphorin 4D as a regulator of tumour cell transmigration through the BBB and MYC as a crucial regulator for the adaptation of DTCs to the activated brain microenvironment [244].

**Lung**

The lung is another organ frequently metastasized by solid tumours such as liver and breast tumours, melanoma, and thyroid tumours [225]. Changes in lung microenvironment in response to a primary tumour can support the survival and outgrowth of metastatic tumour cells. Exosomes carrying integrins α6β4 and α6β1 preferentially accumulate in laminin-rich lung microenvironments, where they enhance S100A4 expression in fibroblasts to establish a proinflammatory PMN and promote lung metastasis [14]. Previous studies also reported that tumour cells could establish a pro-metastatic fibronectin-rich environment via phenotypically modulating perivascular cells in favour of the ensuing lung metastasis [245]. Triple-negative breast cancer types can support their metastatic behaviour through modification of ECM proteins such as fibronectin, tenascin-c and peristin and soluble components including the metastasis-associated proteins CCL7, FGFR4, GM-CSF, MMP3, thrombospondin-1 and VEGF in the lung microenvironment [20]. Moreover, it has been found that highly proinvasive ECM deposited by lung fibroblasts under the influence of mutp53-exosomes is conducive to the metastatic seeding of tumour cells [21]. The pro-metastatic interaction between primary tumour cells and fibroblasts in the lung was also identified in high-metastatic hepatocellular carcinoma [23] and PDAC [22]. Additionally, lung epithelial cells are critical for initiating neutrophil recruitment and lung metastatic niche formation by sensing tumour exosomal RNAs via TLR3 [24]. Neutrophils recruited in large numbers to the inflamed lungs degranulate and release stored proteases that specifically degrade a potent anti-tumorigenic factor, thrombospondin-1, resulting in lung metastasis formation [246]. CCL2 derived from tumour and stromal cells can facilitate lung metastasis by recruiting myeloid cells to lung microenvironments [29, 41, 43]. LOXL2 secreted by breast cancer cells promotes early lung metastasis by controlling the expression of several cytokines and secreted factors and favouring the mobilization and recruitment of CD11b+ myeloid cells to lung microenvironments, without modifying ECM stiffness and collagen organization [247]. PMN-derived SDF-1 contributes to lung colonisation by hepatocellular CTCs [53].

Above all, several determinants of organotropic metastasis such as those involved in the interaction between tumour cells and organ-specific resident cells are only relevant to metastasis in correspondence with particular organs. However, organotropic determinants are not necessarily restricted to the one particular organ, due to similar constituents in different PMNs. For instance, the interaction mediated by co-expressed CD146 and CXCR4/CXCL12 signalling between melanoma cells and resident MSCs/pericytes at the perivascular space regulates the extravasation of melanoma cancer cells to bone marrow and liver [52]. Primary tumours can activate resident fibroblasts both in lung and liver, which promote metastatic cancer growth by secreting proinflammatory cytokines such as IL-6 and IL-8 [15]. Additionally, organ-specific metastasis can also be regulated by intrinsic properties of tumour cells. For example, metastatic organotropism of PDAC is dependent upon epithelial plasticity under the governance of p120-catenin. The expression of p120-catenin is required for liver metastasis, while a lack of p120-catenin significantly shifts the metastatic organotropism to the lungs [248]. Furthermore, in human colorectal cancers, CD110+ and CDCP1+ subpopulations were observed to mediate hepatic and pulmonary metastasis, respectively. CD110+ CSCs promote the formation of liver metastases and CDCP1 promotes adhesion of cancer cells to the lung endothelium [249]. In conclusion, PMNs in different target organs displaying distinct molecular and cellular components contribute to the organotropic features of cancer metastasis. Underlying mechanisms need to be elucidated further.

**Targeting the PMN for cancer therapeutics**

Tumour metastasis remains the greatest challenge in cancer therapy. Given the importance of the PMN for the regulation of cancer metastasis, targeting various components involved in PMN formation and evolution might represent a promising therapeutic strategy against metastasis (Fig. 3). Therapeutic strategies evaluated and under evaluation in humans are summarized in Table 1.

**Prevention of PMN formation**

The components involved in the dynamic process of PMN formation may be potential therapeutic targets to inhibit the formation and function of the PMN, which may be effective in controlling cancer metastasis (Fig. 3a).
The strategy for targeting EVs is widely applicable to tumours in different organs and of different subtypes, essentially because EVs are secreted from nearly all cells, while tumour suppressors have rather narrow applicability because the intrinsic mechanism of cancer metastasis seems to depend on the cancer type. In in vitro and in vivo experiments performed in a mouse model of breast cancer, tumour-derived EVs incubated with the human-specific anti-CD9 or anti-CD63 antibodies were eliminated by macrophages, which significantly decreased metastasis to the lungs, lymph nodes, and thoracic cavity, although no obvious effects on primary xenograft tumour growth were observed [264]. However, the anti-human CD9 and CD63 antibodies are not suitable for direct use in human due to the severe side effects. Targeting exosomal integrins $\alpha_6\beta_4$ (mediating lung tropism metastasis) and $\alpha_5\beta_3$ (mediating liver tropism metastasis) may effectively block the uptake of exosomes by resident cells and the subsequent organ-specific metastasis [14]. The effect of cilenitide, a selective inhibitor of $\alpha_6\beta_4$ and $\alpha_5\beta_3$ integrins, combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated $MGMT$ promoter, was assessed in a phase 3 trial (NCT00689221). However, the addition of cilenitide to temozolomide chemoradiotherapy, unfortunately, did not improve outcomes [250]. This failure might be attributed to the reason that the progression of brain tumours, including glioblastomas, generally does not involve distant organs metastasis. Additionally, a preclinical study showed that an anti-hypertensive drug, reserpine, suppressed tumour-derived EVs uptake and disrupted EV-induced formation of the PMN and melanoma lung metastases, which indicates a great potency of reserpine as an adjuvant therapeutic agent in the context of melanoma therapy [265]. Apart from conventional therapeutic drugs,
## Table 1: Therapeutic strategies against pre-metastatic niche in clinic

| Therapeutic Agent          | Description                                                                 | Phase | Cancer Type | Outcomes                                                                 | Clinical Trials               | References |
|----------------------------|------------------------------------------------------------------------------|-------|-------------|--------------------------------------------------------------------------|-------------------------------|------------|
| Cilengitide                | Integrins (αvβ3 and αvβ5) inhibitor                                          | 3     | Glioblastoma| The addition of cilengitide to temozolomide chemoradiotherapy did not improve overall survival or progression-free survival | NCT00689221 [250]            |            |
| Propagermanium            | CCR2 inhibitor                                                               | 1     | Breast cancer| Propagermanium proved to be safe as an anti-metastatic drug              | UMIN0000022494 [251]         |            |
| 5-azacytidine and entinostat | DNA methyltransferase and histone deacetylase inhibitors                        | 1/2   | Lung cancer | One complete response and one partial response were observed              | NCT00387465 [252]            |            |
|                            |                                                                              | 2     | Breast cancer| One partial response was observed                                       | NCT01349959 [253]            |            |
|                            |                                                                              | 2     | Colorectal cancer| Combination epigenetic therapy proved to be well tolerated but without significant clinical activity | Unknown [254]                 |            |
| Plerixafor                 | CXCR4 inhibitor                                                              | 2     | Pancreatic cancer| Under evaluation                                                        | NCT04177810 N/A              |            |
| Denosumab                  | Anti-RANKL                                                                   | 3     | Breast cancer| Denosumab did not improve bone metastasis-free survival                  | NCT01077154 [255]            |            |
|                            |                                                                              | 3     | Breast cancer| Denosumab reduced the risk of clinical fractures and improved disease-free survival | NCT00556374 [256]            |            |
|                            |                                                                              | 3     | Prostate cancer| Denosumab delayed initial bone metastases                             | NCT00286091 [257]            |            |
| Siltuximab                 | Anti-IL-6                                                                    | 1/2   | Solid tumours| Siltuximab proved to be well tolerated but without clinical activity     | Unknown [258]                 |            |
| Simtuzumab                 | LOXL2 antibody                                                               | 2     | Colorectal cancer| The addition of simtuzumab to FOLFIRI did not improve progression-free survival, overall survival or objective response rate | NCT01479465 [259]            |            |
|                            |                                                                              | 2     | Pancreatic cancer| The addition of simtuzumab to gemcitabine did not improve progression-free survival, overall survival or objective response rate | NCT01472198 [260]            |            |
| Andecaliximab              | Anti-MMP9                                                                    | 3     | Gastric cancer| The addition of andecaliximab to mFOLFOX6 did not improve overall survival | NCT02545304 [261]            |            |
| Maraviroc                  | CCR5 blocker                                                                 | 1     | Colorectal cancer| Anti-tumoral effects were observed at the tissue level                   | NCT01736813 [262]            |            |
|                            |                                                                              | 1     | Colorectal cancer| Under evaluation                                                        | NCT03274804 N/A              |            |
| Galunisertib               | TGF-β receptor inhibitor                                                     | 1b/2  | Pancreatic cancer| The addition of galunisertib to gemcitabine improved overall survival with minimal added toxicity | NCT01373164 [263]            |            |
|                            |                                                                              | 1b/2  | Solid tumours| Under evaluation                                                        | NCT02423343 N/A              |            |
| Canakinumab                | IL-1β inhibitor                                                              | 3     | Lung cancer | Under evaluation                                                        | NCT03631199 N/A              |            |

N/A: Not applicable. RANKL: Receptor activator of NF-κB ligand. LOXL: Lysyl oxidase-like. MMP: Matrix metalloproteinases. TGF-β: Transforming growth factor-β.
gold nanocages embellished with the platelet and neutrophil hybrid cell membrane, defined as nanosponges and nanokillers (NSKs), can simultaneously capture and clear the CTCs and tumour-derived exosomes via high-affinity membrane adhesion receptors, effectively cutting off the connection between exosomes and immune cells [266]. In addition, the delivery of drugs via exosome membrane packaged core-shell nanoparticles is a promising clinical strategy for cancer prevention and therapy as well. For example, exosome membrane-based nanoparticles can facilitate the delivery of therapeutic siS100A4 to the pre-metastatic lungs via exosome membrane-mediated organotropism and, meanwhile, protect siRNA from enzymatic degradation, mediating efficient cancer prevention [267].

Targeting chemokine signalling represents a potential therapeutic strategy against tumour metastasis. CCL2 seems to be a potent therapeutic target in preventing PMN formation due to its important role in the recruitment of BMDCs via binding CCR2 [41]. However, CCL2 has also been reported to be a critical mediator of optimal anti-metastatic entrainment of G-CSF-stimulated neutrophils, and this type of tumour-engaged neutrophils inhibits tumour cell seeding at a distant pre-metastatic site by generating H2O2 [174]. Although neutrophils express CCR2, the possibility of neutrophil entrainment through CC receptors other than CCR2 cannot be excluded. The interruption of CCL2 inhibition leads to an overshoot of metastases and accelerates death due to monocyte release from the bone marrow and enhancement of tumour cell mobilization from the primary site, as well as blood vessel formation and increased proliferation of metastatic tumour cells in the lungs in an IL-6- and VEGF-A-dependent manner [268]. These findings indicate that targeting CCL2, which simultaneously possesses both pro-metastatic and anti-metastatic effects due to different receptors on target cells of different types, may be ineffective in preventing PMN formation and tumour metastasis. Therefore, targeting CCR2 might prove a rational approach for preventing cancer metastasis. Propagermanium, a CCR2 antagonist which is currently administered clinically for the treatment of individuals with a hepatitis B virus infection, was shown to have a marked inhibitory effect on cancer metastasis [269]. A phase 1 dose-escalation study indicated an acceptable safety profile of propagermanium used as an anti-metastatic drug for breast cancer patients [251]. Recently, a preclinical study revealed that adjuvant epigenetic therapy using low-dose DNA methyltransferase and histone deacetylase inhibitors, 5-azacytidine and entinostat, disrupted the PMN by inhibiting the trafficking of both monocytes and granulocytic MDSCs through the downregulation of CCR2 and CXCR2, and by promoting monocytic MDSC differentiation into a more-interstitial macrophage-like phenotype [270]. Such epigenetic therapy alone has been reported with limited therapeutic value in certain metastatic cancers, including lung, breast and colorectal cancer [252–254, 271]. Its priming role in anti-PD1 treatment is under evaluation in a phase 2 clinical trial for non-small cell lung cancer (NCT01928576). Another preclinical experiment related to PDAC demonstrated that AZ13381758, a small-molecule inhibitor of CXCR2 that is related to AZD5069, prevented PMN formation by inhibiting BMDC recruitment and improved T cell infiltration into established metastases [272]. Therefore, CXCR2 inhibition in combination with anti-PD-1 immunotherapy may provide hope for effectively targeting multiple stages of the metastatic process in PDAC. Furthermore, pharmacological inhibition of CXCR4 with AMD3100 was reported to reduce TIMP-1-induced PMN formation and neutrophil infiltration without affecting homeostasis of the hematopoietic system [49]. Targeting CXCR4 is not only important for preventing PMN formation via reducing BMDC recruitment but can act in concert with immunotherapies to confine the growth of established metastases. Plerixafor (AMD3100) treatment was shown to reduce fibrosis, alleviate immunosuppression, and significantly enhance the efficacy of immune checkpoint blockers in preclinical models of metastatic breast cancers [273]. The safety and clinical activity of plerixafor in combination with cemiplimab (anti-PD-1) is under evaluation in a phase 2 clinical trial for metastatic pancreatic cancer (NCT04177810). Concluding the above, we propose that targeting specific chemokine receptors on non-tumour cells but not their ligands may hold great promise in the development of effective therapeutic strategies to prevent PMN formation and ensuing tumour metastasis.

The RANK/RANKL signalling, as discussed before, induces an osteolytic and immunosuppressive PMN in bone via the induction of osteoclastogenesis [66] and Treg expansion [46], which suggests targeting RANK/RANKL will potentially be effective in preventing PMN formation and bone metastasis by tumours. Denosumab is a human monoclonal antibody that targets the RANK L, with high affinity and specificity for the soluble and cell membrane-bound forms of human RANKL [274]. In the latest double-blind, randomised, placebo-controlled, phase 3 trial (NCT01077154), the effect of denosumab in combination with adjuvant or neoadjuvant systemic therapy in women with histologically confirmed stage II or III breast cancer was assessed [255]. Results for the primary endpoint of bone metastasis-free survival uncovered that denosumab did not improve disease-related outcomes for women with high-risk early breast cancer. However, a previous phase 3 trial (NCT00556374) showed that treatment with adjuvant denosumab reduced the risk of clinical fractures and improved
disease-related outcomes in patients with postmenopausal hormone receptor-positive early breast cancer receiving aromatase inhibitor therapy [256]. Moreover, denosumab was also tested in another phase 3 trial (NCT00286091) and was shown to delay initial bone metastases in patients with castration-resistant prostate cancer [257]. In summary, although the exact effect of denosumab in bone metastasis disease should be identified in future studies, denosumab does indicate that the RANK/RANKL signalling pathway, as an important signalling pathway for the establishment of the PMN in bone, can be targeted to improve the bone metastasis-related outcomes of patients with aggressive tumours.

**Targeting the interaction between tumour cell and PMN**

The successful extravasation, colonization and outgrowth of metastatic tumour cells in PMN is a severe rate-limiting step during metastasis progression [275]. Targeting the interactions between tumour cells and PMN may be a novel therapeutic strategy to avert tumour metastasis progression (Fig. 3b).

NETs formed by neutrophils in the PMN can promote metastatic colonization of tumour cells [276, 277]. Therefore, inhibiting NET formation or digesting NETs with deoxyribonuclease I (DNase I) may block metastatic progression. DNase I is approved by the FDA for the treatment of cystic fibrosis, in which it decreases mucus viscosity, resulting from NET accumulation and triggered by persistent infections. DNase I-coated nanoparticles overcome the weakness of short half-life in blood and inhibit tumour metastasis, which serves as proof that NETs are possible drug targets to reduce metastasis [278]. Another strategy to avert NET formation is using a PAD4 pharmacologic inhibitor that has been testified efficient in preventing omental metastasis in a preclinical experiment [276]. Furthermore, NETs can also shield tumour cells from cytotoxicity, as mediated by CD8+ T cells and NK cells, by obstructing close contact with these cytotoxic immune cells [279], indicating that the combination of NET blockade with immunotherapies, such as immune checkpoint inhibitors, represents a promising strategy to prevent metastatic progression. In addition to NETs, leukotrienes derived from tumour-mobilized lung neutrophils aid the tumour colonization of distant tissues by selectively increasing the proliferation of metastasis-initiating tumour cells in a pERK1/2-dependent manner, and Zileuton, an inhibitor of leukotriene-generating enzyme Alox5, abrogates neutrophil pro-metastatic activity and consequently reduces metastasis [175]. It was preclinically demonstrated that endogenous type I IFNs regulated the cellular composition within the PMN by restricting migration of neutrophils and therefore reduced the expression of prometastatic molecules such as S100A8, S100A9, Bv8 and MMP9 and inhibited extravasation efficiency of tumour cells [280]. Therefore, the application of low dose type I IFNs in the perioperative period could be a promising approach reducing the risk of metastases development, especially in patients with impaired type I IFN signalling.

IL-6 derived from PMN endows metastatic tumour cells with proliferative advantages [67, 68, 281] and the resistance to cytotoxic T cells through the overexpression of immunosuppressive molecules like PD-L1 [282], which suggests that IL-6 is a promising target for both restriction of tumour proliferation and restoration of host immunity. Siltuximab, a monoclonal antibody with high binding affinity for human IL-6, was reported in a phase 1/2 trial to be well tolerated but without clinical activity in solid tumours including ovarian and KRAS mutant cancers [258]. Interestingly, a recent study showed that treatment of ovarian cancer cells with neutralizing IL-6 antibodies resulted in upregulated EGFR, whereas the combination of neutralizing IL-6 antibodies and the EGFR inhibitor gefitinib exhibited enhanced anticancer activity [283]. Moreover, EGFR in exosomes secreted from gastric cancer cells can be delivered into the pre-metastatic liver and is integrated on the plasma membrane of liver stromal cells, including Kupffer cells and hStCs, which effectively facilitates the landing and proliferation of metastatic cancer cells [12]. Collectively, it is expected that a combination of IL-6-targeted therapy with EGFR inhibitor gefitinib or other therapies, such as chemo- or immunotherapy like anti-PD-L1, will be more efficient than monotherapy. Although chemotherapy is cytotoxic to tumour cells, its anti-metastatic potential might be compromised by the stromal cells in the PMN. For example, osteoblast-derived Jagged1 activates Notch signalling in tumour cells to promote resistance to chemotherapy-induced apoptosis. The combination of chemotherapy with 15D11, a fully human monoclonal antibody against Jagged1, may nullify such stroma-mediated mechanism of chemoresistance and help achieve optimal outcomes in the treatment of bone metastasis [284].

LOX family proteins, induced mainly by hypoxia, promote PMN evolution and ensuing tumour colonization and proliferation [73–77]. As a result, these hypoxia-induced enzymes are potent mediators of tumour metastasis and promising novel therapeutic targets. Two chemically and mechanistically distinct HIF inhibitors, digoxin and acriflavine, were reported to hinder PMN evolution by blocking the hypoxia-induced expression of LOX family proteins, collagen cross-linking and CD11b+ BMDC recruitment, thus preventing lung metastasis in an orthotopic breast cancer model [285]. Therefore, both digoxin and acriflavine are suitable candidates for clinical trials for breast cancer, especially in those patients whose primary tumours express high levels of HIF-1α. Moreover, inhibition of LOX was demonstrated to lead
to a decrease in collagen crosslinking and subsequently a reduction in the generation of the insoluble fibrotic matrix, thus preventing breast cancer metastasis [286]. However, another animal experiment proved that treatment with β-aminopropionitrile (BAPN), a LOX inhibitor, did not suppress the lymph node metastases [287]. LOXL2 was shown to promote fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist PMN formation [288], whereas a randomized phase 2 trials showed that simtuzumab, an antibody to LOXL2, did not improve clinical outcomes in patients with metastatic KRAS mutant colorectal carcinoma [259] or metastatic pancreatic adenocarcinoma [260]. These seemingly paradoxical outcomes in preclinical studies and clinical trials may be related to the extremely selective nature of specific antibodies that lack cross-inhibition of other LOX family proteins. MMPs were shown to be responsible for ECM modification and vascular destabilization in PMN [51, 74, 152, 289]. The efficacy and safety of anedacliximab, a monoclonal antibody that inhibits MMP9, combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma was evaluated in a phase 3 clinical trial [261]. Regrettably, the results indicated that the addition of anedacliximab to mFOLFOX6 did not improve the overall survival of these patients. Further investigations are needed to explore the exact role of targeting LOX family proteins and MMPs during tumour metastasis and to understand the circumstances under which targeting ECM remodelling may be used as a therapeutic strategy for cancer patients. Additionally, metformin was recently reported to prevent the development of a fibrotic PMN [290], indicating its potential use for precaution against tumour metastasis.

Another major problem in the clinical management of tumour is metastatic dormancy, as it presents a risk of relapse and undermines the benefit of current adjuvant chemotherapies and hormonal therapies as well. Therefore, targeting metastatic tumour dormancy represents a possible way of therapeutically intervening metastasis. A preclinical study demonstrated that GM1-1271, a highly specific glycomimetic E-selectin binding inhibitor, blocked E-selectin on the lumen of specialized vascular beds in the bone marrow, preventing vessel adhesion and subsequent passage of circulating breast cancer cells into the tissue, and that AMD3100 (a CXCR4 inhibitor) forced dormant breast cancer cells, inhabiting these same perivascular niches, into the bloodstream [232]. Simultaneous blockade of CXCR4 and E-selectin could exclude dormant metastatic cancer cells from the protective bone marrow environment and block their re-entry into niches, preventing recurrence. Additionally, E-selectin antagonists were also shown to prevent hematogenous metastasis of breast cancer via the inhibition of a shear-resistant adhesion of cancer cells to E-selectin-expressing blood vessels on the PMN [291, 292].

Targeting the metabolic changes in the PMN may also be a promising therapeutic strategy to prevent tumour metastasis. Breast cancer-secreted miR-122 was reported to suppress glucose uptake by non-tumour cells in the PMN through downregulating the glycolytic enzyme pyruvate kinase, which allowed metastasizing breast cancer cells to accommodate their nutrient requirements of glucose in the PMN and facilitates metastatic seeding [19]. Accordingly, miR-122-targeted therapy in metastatic cancer patients seems highly feasible, and the non-invasive blood test for circulating miR-122 would enable accurate selection of patients who may benefit from this treatment. Moreover, the occurrence of neural niches may allow the use of various available neurotransmitter modulators as metabolically related anti-metastatic drugs. For instance, vigabatrin, an irreversible inhibitor of γ-Aminobutyric acid (GABA) transaminase (ABAT), was experimentally shown to prevent brain metastasis by breast cancer cells by avoiding GABA catabolism [293]. In addition, an artificial PMN fabricated by embedding exosomes onto a 3D scaffold was indicated to be an effective approach to disrupt the process of metastasis through capturing metastatic cells disseminating in the peritoneal cavity [294]. This research suggests that a potent artificial PMN is an effective approach to impair the metastatic cells colonization of the PMN, representing a disruptive technology that complements current surgical and chemotherapeutic approaches in advanced gynecological and gastrointestinal malignancies with a peritoneal dissemination pattern.

**Deconstructing the complexity of the PMN**

Vascular destabilization and immunosuppression, which are major principal characteristics of the PMN, enable the PMN to be suitable for tumour cell extravasation, colonization and proliferation. Targeting these characteristics to deconstruct the complexity of the PMN may be a very promising strategy for metastasis therapeutics (Fig. 3c).

**Vascular stabilization**

Vascular destabilization is crucial for the extravasation of tumour cells and subsequent metastasis and is reflected in many aspects including high vascular permeability, angiogenesis and lymphangiogenesis in the PMN. Ang2 that promotes angiogenesis is highly upregulated in the PMN [62, 152], indicating that it may act as a potential therapeutic target in tumour metastasis. Preclinical data demonstrated that inhibition of Ang2 following primary tumour resection significantly reduced the metastatic burden and exerted an antiangiogenic response with stabilized residual vasculature
in metastases, and that combining Ang2 antibody with low-dose metronomic chemotherapy interfering with the recruitment of the anti-VEGF resistance-conferring myeloid cells further improved the therapeutic benefit with fewer adverse effects than high-dose chemotherapy [295]. Moreover, anti-angiogenic therapies, such as anti-VEGF therapy, were shown to be in synergy with the FDA-approved anti-retroviral drug, maraviroc (CCR5 blocker), which is orally available and safe for long-term use, giving rise to further possibilities of the therapeutic intervention for metastatic breast cancer [64]. The anti-tumour effect of maraviroc was confirmed at the tissue level in patients with liver metastases of advanced refractory colorectal cancer [262] and is, currently, evaluated in a phase 1 clinical trial for metastatic colorectal cancer (NCT03274804). Additionally, VCAM-1 binding peptide tagged liposomes carrying the CCR2 antagonist can reduce pre-metastatic lung vascular permeability by directly targeting cancer cell-activated endothelium, and thereby prevent tumour cell extravasation [296]. A separate preclinical study proved that inhibition of C5aR1 in combination with antiangiogenic Listeria-based vaccines reduced or prevented breast cancer metastasis by reducing vascular density and improving antitumor immunity in the pre-metastatic lungs, and that this therapeutic approach was more efficacious in reducing lung metastatic burden than sunitinib, a small-molecule receptor tyrosine kinase inhibitor that has well-established antiangiogenic properties resulting from its interactions with PDGFR and VEGFR [297]. This combinational strategy has the potential to overcome the resistance to antiangiogenic monotherapies targeting exclusively the VEGF pathway because poor responses to these therapies are driven by the upregulation of alternative proangiogenic pathways, increased protective pericyte coverage of tumour blood vessels and the recruitment of proangiogenic myeloid inflammatory cells, including MDSCs to tumours [297].

Apart from reducing vascular density, vessel normalization seems to be another effective strategy to reverse vascular destabilization in the PMN. LIGHT-VTP, which consists of the TNF superfamily member LIGHT or TNFSF14 and a vascular targeting peptide (VTP) that specifically binds to angiogenic tumour vasculature, efficiently targets pathological blood vessels in the PMN, reducing vascular hyper-permeability and ECM deposition, thus blocking metastatic lung colonization [298]. Moreover, LIGHT-VTP decreases intravasation of tumour cells from the primary sites into the circulation, and also reverses vessel abnormalities and sensitizes tumours for checkpoint inhibitor antibodies against the PD-1 once metastatic nodules have formed [298]. These combinational strategies offer a new therapeutic avenue for the treatment of aggressive metastatic cancers unresponsive to the current therapies. Additionally, preclinical data identified that aspirin, an inhibitor of both cyclooxygenase (COX) isoforms, prevented the formation of an intravascular metastasis and PMN through inhibition of platelet-derived thromboxane A2 (TXA2) [299]. However, aspirin significantly increases the risk of severe gastrointestinal symptoms and complications, especially over long-term use. Therefore, selective TXA2 inhibitors such as picotamide might present an alternative to target platelet-derived TXA2 while sparing other gastroprotective COX-1 products (i.e., prostacyclin), and thus might be a safer therapeutic option for the prevention of metastatic disease [299].

**Immunomodulation**

Deconstructing immunosuppression is a promising therapeutic strategy to inhibit the pro-metastatic properties of the PMN. COX-2-derived PGE2 has been identified as a crucial factor for the accumulation of immunosuppressive cells in the PMN [48, 300]. As a result, it should be targeted to improve the anti-tumour response. Preclinical studies demonstrated that celecoxib, a COX-2 inhibitor, could inhibit the infiltration of immunosuppressive cells in the PMNs and subsequent tumour metastasis in lymph nodes [48] and brain [300]. In another experiment, celecoxib was shown to inhibit lymph node metastasis of breast cancer by cutting off the link between B cell-derived pathogenic IgG and SDF1α secretion by lymph node stromal cells [301]. Tumour-evoked regulatory B cells (tBregs) that are actively generated by normal B cells in response to the direct effects of tumour-derived factors, induce the conversion of metastasis-supporting FoxP3+ Tregs from nonregulatory CD4+ T cells [302] and activate the regulatory function of both the monocyte and granulocyte subpopulations of MDSCs [303], both of which depend on TGF-β signalling, thus inducing an immunosuppressive environment in PMN to support lung metastasis. As a result, tBregs need to be targeted to reduce the expansion and activation of immunosuppressive cell populations such as Tregs and MDSCs, enhancing antitumor immune responses. Clinically available antibodies such as the pan B-cell antibody, anti-CD20 antibody (rituximab) or the anti-IL-2Rα antibody (daclizumab) could bypass the tBreg-mediated blockade of the immune response to some cancers [302]. However, it was preclinically shown that rituximab did not provide benefits in solid tumours, as it enriches for CD20Low tBregs via depletion of the beneficial antitumor CD20+ B cells, and thereby further enhances lung metastasis by exacerbating tBreg-mediated immunosuppression [304]. Therefore, tBreg-targeted therapies should avoid depleting beneficial antitumor B cells. CXCL13-coupled CpG oligonucleotides (CpG-ODN) [304] and resveratrol [305] can efficiently inhibit tBregs without nonspecific inactivation of effector immune cells, representing a promising strategy to enhance cancer therapy by targeting tBregs. Besides, the aforementioned
studies also provide an important rationale for targeting TGF-β in order to improve anti-tumour immune responses. Galunisertib is the first orally bioavailable small-molecule inhibitor of the type I TGF-β receptor (ALK5) serine/threonine kinase to enter clinical development [306]. In a phase 1b/2 trial (NCT01373164), galunisertib in combination with gemcitabine improved overall survival in patients with unresectable pancreatic cancer, with minimal added toxicity, compared with gemcitabine alone [263]. Targeting both TGF-β and immune checkpoint in combination will be an effective approach to suppress tumour metastasis. Clinical trials are currently exploring the combination of anti-PD-1 (nivolumab) and galunisertib in advanced refractory solid tumours (NCT02423343). CCL9, as a downstream mediator of the metastasis-promoting function of TGF-β signalling in MDSCs, may be a good therapeutic target and might bypass some of the negative consequences of TGF-β neutralization [307].

T-cell-intrinsic expression of the oxygen-sensing prolyl-hydroxylase (PHD) proteins was found to suppress anti-tumour immunity in the pre-metastatic lungs through restraining inflammatory CD4+ and CD8+ T cell responses and permitting immunosuppressive Treg differentiation [308]. Therefore, inhibition of PHD proteins could offer a viable clinical strategy to limit lung metastasis. Addition of a PHD inhibitor to established clinical expansion protocols for human adoptive cell therapy (ACT) using tumour-infiltrating lymphocytes (TILs) or chimeric antigen receptor (CAR)-transduced T cells is a feasible and potentially effective therapeutic strategy to improve the functional quality of tumour-specific T cells [309]. Tumour-induced neutrophils also acquire the ability to suppress cytotoxic T lymphocytes carrying the CD8 antigen, which limits the establishment of metastases. For example, IL-1β elicits IL-17 expression from γδ T cells, resulting in a systemic G-CSF-dependent expansion and polarization of neutrophils towards a CD8+ T cell-suppressive phenotype and subsequent metastasis formation in distant organs [309]. Targeting this novel IL-1β/γδ T cell/IL-17/neutrophil axis represents a new strategy to modulate the immunosuppressive state of the PMN and metastatic disease progression. Additionally, IL-1β was found to promote the recruitment of MDSCs and macrophages via chemokine expression [310] and tumour cell arrest on endothelial cells via E-selectin expression [311] in the PMN. Preclinical data demonstrated that anakinra, IL-1 receptor antagonist, limited metastasis, and MDSC recruitment at early stages of tumour progression but failed to reverse established metastatic tumours [310]. Moreover, blocking IL-1β can synergize with anti-PD-1 for tumour abrogation [312]. The efficacy and safety of pembrolizumab (anti-PD-1) plus platinum-based doublet chemotherapy with or without canakinumab (IL-1β inhibitor) as first-line therapy, is currently evaluated in a randomized, double-blind, placebo-controlled, phase 3 study for subjects with locally advanced or metastatic non-squamous and squamous non-small cell lung cancer (NCT03631199).

Conclusion

PMN formation is initiated by the dynamic and complex interaction of tumour cells with the surrounding microenvironment in the primary metastatic site. Investigating this interaction has led to a deeper understanding of the mechanisms underlying metastasis, which could potentially aid in developing new therapeutic strategies to hinder metastatic development. Although several therapeutic approaches have already been introduced, it is still necessary to develop other strategies that will target the PMN more effectively. Additionally, highly sensitive and specific biomarkers are required to identify suitable patients that will benefit from these anti-metastatic therapies. The use of animal models and other experimental techniques is needed to further illuminate the biological network within the PMN and will potentially help the clinical translation of niche-targeted approaches. Applying niche-targeted therapies together with other anti-tumour therapies holds great promise for the effective prevention of metastasis.

Abbreviations

BBB: Blood-brain barrier; BMDCs: Bone marrow-derived cells; CAF: Carcinoma-associated fibroblast; COX: Cyclooxygenase; CSCs: Cancer stem cells; CTCs: Circulating tumour cells; DCS: Dendritic cells; DTCs: Disseminated tumour cells; ECM: Extracellular matrix; EGFR: Epidermal growth factor receptor; EVs: Extracellular vesicles; FGF: Fibroblast growth factor; G-CSF: Granulocyte-colony stimulating factor; GAG: Glycosaminoglycan; HA: Hyaluronan; HIF: Hypoxia-inducible factor; HSCs: Hematopoietic stem cells; hStCs: Hepatic stellate cells; IL: Interleukin; LECs: Lymphatic endothelial cells; LOX: Lysyl oxidase; LOXL: Lysyl oxidase-like; MAMs: Metastasis-associated macrophages; MDSCs: Myeloid-derived suppressor cells; MMP: Matrix metalloproteinases; MSCs: Mesenchymal stem cells; NET: Neutrophil extracellular trap; NOX2: NADPH oxidase 2; PD-1: Programmed death-1; PD-L1: Programmed death-ligand 1; PDAC: Pancreatic ductal adenocarcinoma; PMN: Pre-metastatic niche; RANK: Receptor activator of NF-κB; RANKL: Receptor activator of NF-κB ligand; SAA: Serum amyloid A; SDF-1: Stromal-derived factor 1; TAMs: Tumour-associated macrophages; TBregs: Tumour-evoked regulatory B cells; TGF-β: Transforming growth factor-β; TLR: Toll-like receptor; TNF: Tumour necrosis factor; Tregs: Regulatory T cells; VCAM-1: Vascular cell adhesion molecule-1; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor

Acknowledgements

The authors would like to thank Hangzhou Dixiang Co. Ltd., Hangzhou, China for help with retouching the figures.

Code availability

Not applicable.

Authors’ contributions

Manuscript composition: HW, JJP, YZ, CG, SW, RV. Manuscript revision: LXQ, QZD, RV. Manuscript review: WWZ, HTS, LL, HLJ, YZ, CB. Manuscript supervision: LXQ, QZD, RV. All authors read and approved the final manuscript.
Funding
This work was supported by the National Key Research and Development Program of China (No. 2017YFC1308604), the National Natural Science Foundation of China (No. 81772563, 81802903 and 81930074), the Program of Shanghai Academic Research Leader (20XD140900), the Joint Tackling Project of Emerging Frontier Technologies in Shanghai Hospitals in 2017 (SHDC12017122) and the NSFC Program of International Cooperation and Exchanges (No. 81121008016).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute & Institutes of Biomedical Sciences, Fudan University, 12 Urumqi 8. Zhu L, Sun H-T, Wang S, Huang S-L, Zheng Y, Wang C-Q, et al. Isolation and characterization of exosomes for cancer research. J Hematol Oncol. 2020;13(1):152. https://doi.org/10.1186/s13045-020-00987-y.
2. Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Nat Genet. 2014;46(6):569–70. https://doi.org/10.1038/ng.3094.
3. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1898;133(421):571–3. https://doi.org/10.1016/S1045-6182(01)7516-0.
4. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9. https://doi.org/10.1038/ncb1596.
5. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Tumour-derived exosomal miRNAs mediate metastasis. Nature. 2015;527(7578):359–63. https://doi.org/10.1038/nature15756.
6. Redzic JS, Balaj L, van der Vos KE, Breakefield XO. Extracellular RNA mediates genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9. https://doi.org/10.1038/ncb1596.
7. Wang H, Yu Y, Zhou L, Ma J, Tang K, Xu P, et al. Circulating tumor microparticles promote lung metastasis by reprogramming inflammatory and mechanical niches via a macrophage-dependent pathway. Cancer Immunol Res. 2018;6(10):1046–56. https://doi.org/10.1158/2326-6066.CIR-17-0574.
8. Liu Y, Gu Y, Han Y, Zhang Q, Jiang Z, Zhang X, et al. Tumor exosomal RNAs promote lung metastasis by activating alveolar epithelial TLRI to recruit neutrophils. Cancer Cell. 2016;30(2):243–56. https://doi.org/10.1016/j.ccell.2016.06.021.
9. Hoshino A, Costa-Silva B, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35. https://doi.org/10.1038/nature15756.
10. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9. https://doi.org/10.1038/ncb1596.

References
1. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28. https://doi.org/10.1038/s41398-020-0134-x.
2. Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668–81. https://doi.org/10.1016/j.ccell.2016.05.011.
3. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1898;133(421):571–3. https://doi.org/10.1016/S1045-6182(01)7516-0.
4. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9. https://doi.org/10.1038/ncb1596.
5. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Tumour-derived exosomal miRNAs mediate metastasis. Nature. 2015;527(7578):359–63. https://doi.org/10.1038/nature15756.
6. Redzic JS, Balaj L, van der Vos KE, Breakefield XO. Extracellular RNA mediates genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9. https://doi.org/10.1038/ncb1596.
7. Wang H, Yu Y, Zhou L, Ma J, Tang K, Xu P, et al. Circulating tumor microparticles promote lung metastasis by reprogramming inflammatory and mechanical niches via a macrophage-dependent pathway. Cancer Immunol Res. 2018;6(10):1046–56. https://doi.org/10.1158/2326-6066.CIR-17-0574.
8. Liu Y, Gu Y, Han Y, Zhang Q, Jiang Z, Zhang X, et al. Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLRI to recruit neutrophils. Cancer Cell. 2016;30(2):243–56. https://doi.org/10.1016/j.ccell.2016.06.021.
9. Hoshino A, Costa-Silva B, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35. https://doi.org/10.1038/nature15756.
10. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9. https://doi.org/10.1038/ncb1596.
49. Seubert B, Goshino A, Kenific CM, Matei IR, Steiner L, Freitas D, et al. Tumor exosomal CEMP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019;21(11):1403–12. https://doi.org/10.1038/s41555-019-0404-4.

50. Grünwald B, Harant V, Schaten S, Frühschütz M, Spallek R, Höcht B, et al. Pancreatic premalignant lesions secrete tissue inhibitor of metalloproteinases-1, which activates hepatic stellate cells via CD63 signaling to create a premetastatic niche in the liver. Gastroenterology. 2016;151(5):2191–21.e7. https://doi.org/10.1053/j.gastro.2016.07.043.

51. Kaplan RN, Riba RD, Zacharewski S, Bramley AH, Vincent L, Costa C, et al. VEGF-R1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature. 2005;438(7069):820–7. https://doi.org/10.1038/nature04186.

52. Correa D, Somoza RA, Lin P, Schemmann WP, Caplan AI. Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche. Int J Cancer. 2016;138(2):417–27. https://doi.org/10.1002/ijc.29709.

53. Tang Y, Lu Y, Chen Y, Luo L, Cai L, Peng B, et al. Pre-metastatic niche triggers SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Pmx1. J Exp Clin Cancer Res. 2019;38(1):473. https://doi.org/10.1186/s13046-019-1475-6.

54. Deng Z, Ji Y, Lee H, Hermann M, Zhang W, Zhang C, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell. 2012;21(5):642–54. https://doi.org/10.1016/j.ccc.2012.03.039.

55. Zhang W, Zhang C, Li W, Deng J, Hermann A, Priceman SJ, et al. CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. Eur J Immunol. 2015;45(1):71–81. https://doi.org/10.1002/eji.201446767.

56. Vadevru SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, et al. Complement C5a receptor facilitates cancer cell metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 2014;74(13):4354–65. https://doi.org/10.1158/0008-5472.CAN-14-0157.

57. Sharma SK, Chintala NK, Vadevru SK, Patel J, Karbowicz M, Markiewski MW. Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs. J Immunol. 2015;194(11):5529–38. https://doi.org/10.4161/onci.1.2.18480.

58. Wang Z, Xiong S, Mao Y, Chen M, Ma X, Zhou X, et al. Periostin promotes immunosuppressive premetastatic niche formation to facilitate breast tumour metastasis. J Pathol. 2016;239(4):484–95. https://doi.org/10.1002/path.4747.

59. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8(12):1369–75. https://doi.org/10.1038/ncb1507.

60. Kim KJ, Kwon SH, Yun JH, Jeong HS, Kim HR, Lee EH, et al. STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression. Oncogene. 2017;36(39):4545–59. https://doi.org/10.1038/onc.2017.148.

61. Wieland E, Rodriguez-Vita J, Liebler SS, Mogler C, Moll I, Herberich SE, et al. Endothelial Notch1 activity facilitates metastasis. Cancer Cell. 2017;31(3):355–67. https://doi.org/10.1016/j.ccell.2017.01.007.

62. Minami T, Jiang S, Schadler K, Szust S, Wang Z, Osawa T, Oike Y, et al. Pro-inflammatory premetastatic niche formation in LNCaP prostate cancer cells correlates with the expression of pro-inflammatory chemokine CCL5. J Immunol. 2011;187(10):5346–53. https://doi.org/10.4161/onci.1.2.18480.

63. Hiratsuka S, Ishibashi S, Tomita T, Watanabe A, Akashi-Takamura S, Murakami M, et al. Primary tumours modulate innate immune signalling to create premetastatic vascular hyperpermeability foci. Nat Commun. 2013;4:1833. https://doi.org/10.1038/ncomms2856.

64. Lee E, Fertig EJ, Jiri K, Sukumar S, Pandey NB, Popel AS. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote immune evasion. Nat Commun. 2014;5:5175. https://doi.org/10.1038/ncomms5715.

65. Olmeda D, Cerezo-Wallis D, Rivero-Falkenbach E, Penacchi PC, Contreras-Alcalde M, Ibzar N, et al. Whole-body imaging of lymphovascular niches predicts metastatic behavior. Cancer Discov. 2019;9(9):1037–52. https://doi.org/10.1158/2326-6066.CD-19-0475.

66. Chu GC, Zhao H, Wang B, Rogatko A, Feng X, Zayazafo A, et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer. 2014;21(23):1131–6. https://doi.org/10.1530/erc-13-0548.

67. Wu JB, Yin L, Shi C, Li Q, Duan P, Huang JM, et al. MAOA-dependent activation of Shh-L6-RANKL signaling network promotes prostate cancer metastasis.

---

Wang et al. Molecular Biomedicine (2021) 2:3 Page 25 of 32
metastasis by engaging tumor-stromal cell interactions. Cancer Cell. 2017;31(3):368–82. https://doi.org/10.1016/j.ccell.2017.02.003.

68. Sethi N, Dai X, Winter CG, Yang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011;19(2):192–205. https://doi.org/10.1016/j.ccc.2011.02.022.

69. Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019;567(7747):249–52. https://doi.org/10.1038/s41586-019-0044-y.

70. Chen WX, Yu TJ, Zhang J, Li Y, Chen HL, Yang GF, et al. CYR61 in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis. Oncogene. 2017;36(35):5045–57. https://doi.org/10.1038/onc.2017.118.

71. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8-serum amyloid A3-Thrombin paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10(11):1349–55. https://doi.org/10.1038/ncb1794.

72. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2014;159(6):945–55. https://doi.org/10.1016/j.cell.2014.06.006.

73. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A. 2011;108(39):16369–74. https://doi.org/10.1073/pnas.1113831108.

74. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the pre-metastatic niche. Cancer Cell. 2009;15(1):35–44. https://doi.org/10.1016/j.ccc.2008.11.012.

75. Cox TR, Runney RMH, Schoof EM, Penynam L, Heye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106–10. https://doi.org/10.1038/nature14492.

76. Reynaud C, Ferreras L, Di Mauro P, Kan C, Croset M, Bonnelye E, et al. Lysyl oxidase activity at pre-metastatic niches. Mol Carcinog. 2020;59(3):323–32. https://doi.org/10.1002/mc.23157.

77. Carbonic anhydrase IX promotes myeloid-derived suppressor cell infiltration into tumors and instigates metastasis. Hepatology. 2014;60(5):1645–58. https://doi.org/10.1002/hep.27320.

78. Chafe SC, Lou Y, Sceneay J, Vallejo M, Hamilton MJ, McDonald PC, et al. Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of a metastatic niche by stimulating G-CSF production. Cancer Res. 2015;75(6):996–1008. https://doi.org/10.1158/0008-5472.Can-14-3000.

79. Wang T, Gilkes DM, Takeno N, Xiang L, Luo W, Bishop CJ, et al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci U S A. 2014;111(13):E3234–42. https://doi.org/10.1073/pnas.1400411111.

80. Ged J, Jain A, Kumar A, Agarwal C, Kim S, Talbot LJ, et al. Exosomes secreted by prostate cancer cells under hypoxia promote matrix metalloproteinase activity at pre-metastatic niches. Mol Carcinog. 2020;59(3):323–32. https://doi.org/10.1002/mc.23157.

81. Doglioni G, Parik S, Fendt SM. Interactions in the (pre)metastatic niche. Front Oncol. 2019;9:219. https://doi.org/10.3389/fonc.2019.00219.

82. Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, et al. Molecular Biomedicine 3389/fonc.2019.00219. 59(3):323

83. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. https://doi.org/10.1038/s41573-018-0004-1.

84. Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. https://doi.org/10.3389/fimmu.2019.01835.

85. Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86. https://doi.org/10.1186/s13045-019-0770-1.

86. Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146(4):895–905. https://doi.org/10.1002/ijc.32193.

87. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncology. 2005;7(4):452–64. https://doi.org/10.1017/s11285705000222.

88. Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. https://doi.org/10.3389/fimmu.2019.01835.

89. Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86. https://doi.org/10.1186/s13045-019-0770-1.
metastasis. Carcinogenesis. 2011;32(4):477–87. https://doi.org/10.1093/carcin/bgr009.

112. Ren G, Esposito M, Kang Y. Bone metastasis and the metastatic niche. J Mol Med (Berl). 2015;93(11):1203–12. https://doi.org/10.1007/s00109-015-1239-4.

113. Zhang W, Bado I, Wang H, Lo HC, Zhang XH. Bone metastasis: find your niche and fit in. Trends Cancer. 2019;5(5):91–100. https://doi.org/10.1016/j.trecan.2018.12.004.

114. Cella-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 2016;30(8):892–908. https://doi.org/10.1101/gad.277881.116.

115. Baccelli I, Trippu A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012;198(3):281–93. https://doi.org/10.1083/jcb.201202014.

116. Oksanen T, Batle F, Massagué J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014;14(3):306–21. https://doi.org/10.1016/j.stem.2014.02.002.

117. Liu S, Ginestier C, Ou SJ, Cloughier SG, Patel SH, Monville F, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine network. Cancer Res. 2011;71(2):614–24. https://doi.org/10.1158/0008-5472.Can-10-0538.

118. Pieks V, Kong N, Werb Z. The cancer stem cell niche: how is it regulated? Stemness of tumors? Cell Stem Cell. 2015;16(3):225–38. https://doi.org/10.1016/j.stem.2015.02.015.

119. Frantz C, Stewart KM, Werb Z. The extracellular matrix in tumor progression and metastasis: a dynamic relationship of breast cancer cells and fibroblasts in fibronectin accumulation at primary and metastatic tumor sites. Cancers (Basel). 2020;12:687. https://doi.org/10.3390/cancers1206687.

120. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in cancer progression: therapeutic implications. J Hematol Oncol. 2010;11(16):4. https://doi.org/10.1186/jhmo.2010.16.16.

121. Gattazzo F, Urciuolo A, Bonaldo P. Extracellular matrix alterations in metastatic processes. Clin Exp Metastasis. 2019;36(3):171–80. https://doi.org/10.1007/s10585-019-09966-1.

122. Wang JP, Hielshcer A. Fibronectin: how its aberrant expression in tumors may improve therapeutic targeting. J Cancer. 2017;8(4):674–82. https://doi.org/10.7150/jca.16901.
158. Jackstadt R, van Hoof SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, et al. Epithelial NOTCH signaling Rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell. 2019;36(3):319–36.e7. https://doi.org/10.1016/j.ccell.2019.03.003.

159. Sun C, Mazzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52. https://doi.org/10.1016/j.immuni.2018.03.014.

160. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–6. https://doi.org/10.1038/s41586-018-0392-8.

161. Lukanditi E, Sleeiman JP. Building the niche: the role of the S100 proteins in metastatic growth. Semin Cancer Biol. 2012;22(3):216–25. https://doi.org/10.1016/j.semcancer.2012.02.006.

162. Brennink AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15(5):96–109. https://doi.org/10.1038/nrc3893.

163. Tomita T, Sakurai Y, Ishibashi S, Maru Y. Imbalance of Clara cell-mediated fructose metabolism drives metabolic reprogramming of colon cancer. Cell. 2015;160(3):593–606.e4. https://doi.org/10.1016/j.cell.2014.12.018.

164. Deguchi A, Tomita T, Ohto U, Takemura K, Kitao A, Akashi-Takamura S, et al. Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFβRII-p38MAPK-pS249/T252RB pathway. Cancer Res. 2018;78(11):2911–24. https://doi.org/10.1158/0008-5472.Can-17-1051.

165. Pommer A, Anaparthi Y, Memos N, Kelley ZL, Gourdonne A, Yan R, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018;360(6394). https://doi.org/10.1126/science.aao4908.

166. Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2019;36(3):319–36.e7. https://doi.org/10.1016/j.ccell.2019.03.003.

167. Shu S, Yang Y, Allen CL, Maguire Q, Minderman H, Sen A, et al. Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep. 2018;8(1):12905. https://doi.org/10.1038/s41598-018-31232-7.

168. Patel S, Fu S, Mastio J, Dominguez GA, Purohit A, Kossenkov A, et al. Unique pattern of neutrophil migration and function during tumor progression. Nat Immunol. 2018;19(11):1236–44. https://doi.org/10.1038/s41590-018-0149-4.

169. Michelet X, Dyck L, Hogan A, Loots RM, Duquette D, Wei K, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol. 2018;19(12):1330–40. https://doi.org/10.1038/s41591-018-0225-1.

170. Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, et al. Extracellular acidification and anaerobic glycolysis contribute to breast cancer metastasis. FEBS J. 2018;285(4):665–86. https://doi.org/10.1111/febs.14206.
immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 2016;29(6):832–45. https://doi.org/10.1016/j.ccell.2016.04.014.

273. Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adatamongkonkul P, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A. 2019;116(10):5459–66. https://doi.org/10.1073/pnas.1815515116.

274. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401–19. https://doi.org/10.1038/nrd3705.

275. Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell. 2013;27(3):228–40. https://doi.org/10.1016/j.ccell.2013.02.007.

276. Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019;216(1):176–94. https://doi.org/10.1084/jem.20181170.

277. Yang L, Liu Q, Zhang X, Liu X, Zhou B, Chen J, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CXCDC25. Nature. 2020. https://doi.org/10.1038/s41586-020-2394-6.

278. Park J, Wysokić RW, Amoozgar Z, Maiorino L, Fein MR, Joms J, et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med. 2016;8(361):361ra138. https://doi.org/10.1126/scitranslmed.aag1171.

279. Teijeira A, Garasa S, Gato M, Alfarro C, Miguelz I, Ciella A, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020. https://doi.org/10.1016/j.immuni.2020.03.001.

280. Wu CF, Andzinski L, Kaisnt N, Kröger A, Klawnon F, Lienknlaus S, et al. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung. Int J Cancer. 2015;137(4):837–47. https://doi.org/10.1002/ijc.29444.

281. Wang Y, Chu Y, Ren X, Xiang H, Xi Y, Ma X, et al. Epidural adipose tissue-mediated inactivation of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 2015;75(24):5283–9. https://doi.org/10.1158/0008-5472.Can-14-3077.

282. Bösendorfer W, Damodaran S, Bologod M, Gress RE, Sen R, Wejksza K, et al. Targeted delivery of CD20 small molecule inhibitor of transforming growth factor-beta signaling prevents metastasis. J Immunol. 2015;204(4):990–1000. https://doi.org/10.4049/jimmunol.1500120.

283. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, et al. Clinical development of galunisertib (LY2157299 monohydrate), a selective small molecule inhibitor of transforming growth factor-beta signaling. Drug Dev Deliv. 2015;45.

284. Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci U S A. 2014;111(3):984–9. https://doi.org/10.1073/pnas.1320981111.

285. de la Fuente A, Alonso-Alconada L, Costa C, Cueva J, García-Caballero T, Lopez-Rojas R, et al. M-trap: exosome-based capture of tumor cells as a new technology in peritoneal metastasis. J Natl Cancer Inst. 2015;107(9). https://doi.org/10.1093/jnci/djv487.

286. Wang Y, Chu Y, Ren X, Xiang H, Xi Y, Ma X, et al. Epidural adipose tissue-mediated inactivation of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 2015;75(24):5283–9. https://doi.org/10.1158/0008-5472.Can-14-3077.
309. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–8. https://doi.org/10.1038/nature14282.

310. Cheng R, Billet S, Liu C, Haldar S, Choudhury D, Tripathi M, et al. Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells. Oncogene. 2020;39(7):1543–56. https://doi.org/10.1038/s41388-019-1084-z.

311. Shi H, Zhang J, Han X, Li H, Xie M, Sun Y, et al. Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1β-mediated increase in E-selectin expression. Int J Cancer. 2017;140(6):1370–83. https://doi.org/10.1002/ijc.30538.

312. Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, et al. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019;116(4):1361–9. https://doi.org/10.1073/pnas.1812266115.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.